Dexamethasone
Small molecule targets HDAC2 via activation
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | DEXTENZA | — | 2019-06-20 – 2025-04-07 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | OZURDEX | — | 2010-09-24 – 2014-06-28 | fda.gov ↗ |
| Approved | EU (EMA) | Ozurdex | — | 2010-07-26 | europa.eu ↗ |
| Approved | US (FDA) | DECADRON | — | 1958-10-30 | fda.gov ↗ |
Trials 1,737 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 030 trials | ||||||
| Phase 0 | NCT07662200 | Aug 2026 → Aug 2027 expected | malignant germ cell tumor | Ottawa Hospital Research Institute | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07343817 | Jul 2026 → Apr 2028 expected | — | Ahmed Nassar Ibrahim Mohammed | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07109258 | May → Sep 2025 overdue | — | Cairo University | Recruiting | No outcome recorded |
| Phase 0 | NCT06428630 | May 2025 → Sep 2026 | lichen planus, oral | Tufts University | Withdrawn | No outcome recorded |
| Phase 0 | NCT06894069 | Mar → May 2025 overdue | — | University of Jordan | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06432712 | Jan 2025 | — | Shoaib Rahim | Unknown | No outcome recorded |
| Phase 0 | NCT06142396 | Nov 2024 → Nov 2027 expected | kidney failure, plasma cell myeloma | Augusta University | Recruiting | No outcome recorded |
| Phase 0 | NCT06556095 | Sep 2024 → Jan 2026 | — | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 0 | NCT05994183 | Oct 2023 → Mar 2025 | bronchiolitis | IDeA States Pediatric Clinical Trials Network | Withdrawn | No outcome recorded |
| Phase 0 | NCT06016465 | Sep 2023 → Dec 2027 expected | migraine disorder | Texas Tech University Health Sciences Center, El Paso | Recruiting | No outcome recorded |
| Phase 0 | NCT05560399 | Feb 2023 → Nov 2026 expected | plasma cell myeloma | Icahn School of Medicine at Mount Sinai | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05620901 | Feb 2023 → Feb 2025 | Coats disease, exudative vitreoretinopathy, retinal lattice degeneration, retinal perforation +1 | Lejla Vajzovic, MD, FASRS | Completed | No outcome recorded |
| Phase 0 | NCT04984330 | Dec 2021 → Jun 2023 | AL amyloidosis | Weill Medical College of Cornell University | Withdrawn | No outcome recorded |
| Phase 0 | NCT04546126 | Nov 2021 → Dec 2026 expected | hypertensive disorder | Benjamin Viglianti | Recruiting | No outcome recorded |
| Phase 0 | NCT04895592 | Jul 2021 → Sep 2023 | metastatic malignant neoplasm in the brain | Emory University | Completed | No outcome recorded |
| Phase 0 | NCT04889547 | Jul 2021 → Jul 2023 | — | Northwell Health | Completed | No outcome recorded |
| Phase 0 | NCT04945824 | Jun 2021 → Nov 2022 | — | Ocular Therapeutix, Inc. | Terminated | No outcome recorded |
| Phase 0 | NCT04418999 | Sep 2020 → Dec 2021 | dry eye syndrome, eye allergy, keratoconus | Illinois College of Optometry | Completed | No outcome recorded |
| Phase 0 | NCT04514029 | Aug 2020 → Nov 2023 overdue | lymphoma | Masonic Cancer Center, University of Minnesota | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04019834 | Jul 2020 → Nov 2021 | breast cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 0 | NCT04037605 | Feb 2020 → Jul 2022 overdue | — | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03719105 | Mar 2019 → Dec 2027 expected | aggressive NK-cell leukemia | New York Medical College | Recruiting | No outcome recorded |
| Phase 0 | NCT03512223 | Oct 2018 → Oct 2024 | — | Ohio State University | Completed | No outcome recorded |
| Phase 0 | NCT03122756 | Aug 2017 → Oct 2018 | — | Ain Shams Maternity Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT02921893 | Oct 2016 → Apr 2022 | POEMS syndrome, plasmacytoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT02318433 | Dec 2014 → Jul 2019 | osteoarthritis | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT02109861 | Jan 2014 → Dec 2015 | plasma cell myeloma | Henrik Gregersen | Unknown | No outcome recorded |
| Phase 0 | NCT01878708 | Jul 2013 → Feb 2017 | T-cell non-Hodgkin lymphoma | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
| Phase 0 | NCT02142543 | Mar → Dec 2012 | aphthous stomatitis | Texas A&M University | Completed | No outcome recorded |
| Phase 0 | NCT00314743 | Oct 2005 → Dec 2008 | — | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1117 trials | ||||||
| Phase 1 | NCT07341867 | Aug 2026 → Mar 2028 expected | plasma cell myeloma, triple-negative breast carcinoma | Andrew Hantel, MD | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07513129 | Jun 2026 → Dec 2029 expected | T-cell acute lymphoblastic leukemia | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT07426042 | Apr → May 2026 overdue | — | Min Kyu Park | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07014462 | Sep 2025 → Jun 2029 expected | acute myeloid leukemia | University of Vermont | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT07182110 | Aug 2025 → Aug 2026 overdue | gallbladder disorder | Makassed General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06348108 | Jul 2025 → Jul 2027 expected | plasma cell myeloma | Alfred Chung, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT06863259 | May 2025 → Jan 2028 expected | B-cell acute lymphoblastic leukemia | Children's Hospital Medical Center, Cincinnati | Recruiting | No outcome recorded |
| Phase 1 | NCT05773664 | Nov 2024 | glioblastoma | City of Hope Medical Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT06433947 | Aug 2024 → Jul 2026 overdue | plasma cell myeloma | Opna Bio LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT06304909 | May 2024 → Mar 2025 | — | Assiut University | Completed | No outcome recorded |
| Show all 117 trials opens the full record — a long page | ||||||
| Phase 1/2101 trials | ||||||
| Phase 1/2 | NCT06574048 | Jul 2026 → Jul 2027 expected | carbon monoxide-induced parkinsonism | University of Nebraska | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07479979 | Jul 2026 → Jul 2027 expected | plasma cell myeloma | Natalie Callander | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07601100 | Jun 2026 → Jul 2029 expected | plasma cell myeloma | Dana-Farber Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06930690 | Jun → Dec 2026 expected | — | The Methodist Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07504822 | Apr 2026 → Mar 2027 expected | acne | Yohanes Firmansyah, dr, MH, MM | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07388069 | Dec 2025 → Dec 2026 expected | keratoconus | TheiaNova Ltd. | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT06892522 | Jun 2025 → Feb 2036 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06235567 | Apr 2025 → Aug 2026 overdue | keratoconus | Maanasa Indaram, MD | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT07024043 | Mar → Sep 2025 overdue | — | Ain Shams University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06176027 | Oct 2024 → Sep 2028 expected | peripheral T-cell lymphoma, not otherwise specified | Navy General Hospital, Beijing | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06559553 | Sep 2024 → Dec 2026 expected | T-cell and NK-cell neoplasm | Mingzhi Zhang | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05486481 | Jan 2024 → Dec 2028 | AL amyloidosis | Alfred Chung, MD | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT06246162 | Nov 2023 → Nov 2025 overdue | plasma cell myeloma | Affiliated Hospital of Nantong University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06082934 | Nov 2023 → Nov 2026 expected | acute lymphoblastic leukemia | Xijing Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06050512 | Oct 2023 → Oct 2026 | refractory plasma cell neoplasm | Kathleen Dorritie | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05857982 | May 2023 → Jan 2025 | refractory plasma cell neoplasm | Second Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05647512 | Jan 2023 → Dec 2024 | plasma cell myeloma | LaNova Medicines Limited | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05434689 | Jan 2023 → Aug 2028 expected | plasma cell myeloma | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05493618 | Dec 2022 → Nov 2025 | plasma cell myeloma | Hackensack Meridian Health | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04947189 | Nov 2022 → Jul 2026 overdue | triple-negative breast carcinoma | St Vincent's Hospital, Sydney | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05451771 | Oct 2022 → Sep 2027 expected | AL amyloidosis | Columbia University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05432934 | Sep 2022 → Mar 2024 | Crohn disease, colorectal cancer | University of Saskatchewan | Unknown | No outcome recorded |
| Phase 1/2 | NCT05422027 | Jul 2022 → Jun 2025 | plasma cell myeloma | Xia Zhongjun | Unknown | No outcome recorded |
| Phase 1/2 | NCT05136560 | Mar 2022 → Feb 2026 | infectious disease with sepsis | CHA University | Completed | No outcome recorded |
| Phase 1/2 | NCT05060627 | Dec 2021 → Oct 2024 overdue | plasma cell myeloma | PETHEMA Foundation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04973605 | Sep 2021 → Nov 2026 expected | refractory plasma cell neoplasm | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04766853 | Jul 2021 → Apr 2023 | Meniere disease, drug-induced hearing loss, noise induced hearing loss, sudden hearing loss disorder | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT04551131 | Jul 2021 → Nov 2025 overdue | hemophagocytic syndrome | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04037462 | Jul 2021 → Feb 2022 | non-small cell lung carcinoma | VA Office of Research and Development | Terminated | No outcome recorded |
| Phase 1/2 | NCT04891744 | Jul 2021 → Dec 2024 | plasma cell myeloma | Li Zheng | Unknown | No outcome recorded |
| Phase 1/2 | NCT04225611 | Mar 2021 → Dec 2027 expected | cystoid macular edema | Massachusetts Eye and Ear Infirmary | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04762745 | Feb 2021 → Feb 2022 | plasma cell myeloma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04300556 | Aug 2020 → Aug 2030 expected | cancer | Eisai Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03952377 | Nov 2019 → Feb 2022 | radiculopathy | SpineThera Australia PTY LTD | Terminated | No outcome recorded |
| Phase 1/2 | NCT04118296 | Oct → Nov 2019 | acne | Sukma Skin Treatment | Completed | No outcome recorded |
| Phase 1/2 | NCT04126200 | Oct 2019 → Apr 2025 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04066647 | May → Jul 2019 | — | Cedars-Sinai Medical Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT03687931 | Aug 2018 → Feb 2019 | eye adnexa disorder | iDrop, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03481556 | Apr 2018 → Feb 2022 | plasma cell myeloma | Oncopeptides AB | Terminated | No outcome recorded |
| Phase 1/2 | NCT03892421 | Apr 2018 → Jan 2021 | non-Hodgkin lymphoma | La Raza Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03492138 | Mar 2018 → Jan 2020 | plasma cell myeloma | Ajai Chari | Terminated | No outcome recorded |
| Phase 1/2 | NCT02545907 | Sep 2017 → Sep 2019 | amyloidosis | University College, London | Completed | No outcome recorded |
| Phase 1/2 | NCT03220113 | Jul 2017 → Jul 2018 | migraine with aura, migraine without aura | Corona Doctors Medical Clinics, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT03236792 | Jun 2017 → Sep 2022 | AL amyloidosis | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 1/2 | NCT03040011 | Jun 2017 → Apr 2019 | pelvic organ prolapse | Lauren Giugale, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT02802163 | Jun 2017 → Sep 2020 | plasma cell myeloma | H. Lee Moffitt Cancer Center and Research Institute | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03033316 | Jan 2017 → Aug 2020 | plasma cell myeloma | Enceladus Pharmaceuticals BV | Terminated | No outcome recorded |
| Phase 1/2 | NCT02971982 | Oct 2016 → Oct 2018 | — | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02937571 | Oct 2016 → Oct 2024 | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02817347 | Jun 2016 → Apr 2017 | discharging ear, otitis media | Yuhan Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT02685826 | Apr 2016 → Dec 2017 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02571556 | Nov 2015 → Oct 2016 | cataract 50 with or without glaucoma | Eyegate Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02542657 | Oct 2015 → Aug 2025 overdue | plasma cell myeloma | Joseph Tuscano | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02343042 | Oct 2015 → Apr 2027 expected | plasma cell myeloma | Karyopharm Therapeutics Inc | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02485249 | Jul 2015 → Jun 2016 | macular retinal edema | Eyegate Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT02389543 | Jul 2015 → Jan 2018 | plasma cell myeloma | Karyopharm Therapeutics Inc | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02348216 | Apr 2015 → Jul 2023 | follicular lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma | Kite, A Gilead Company | Completed | No outcome recorded |
| Phase 1/2 | NCT02006147 | Nov 2014 → Jul 2020 | central retinal vein occlusion with macular edema, occlusion of tributary of retinal vein | Taiwan Liposome Company | Completed | No outcome recorded |
| Phase 1/2 | NCT02309385 | Oct 2014 → Mar 2017 | non-infectious anterior uveitis | Aciont Inc | Completed | No outcome recorded |
| Phase 1/2 | NCT02204241 | Jun 2014 → Jun 2015 | plasma cell myeloma | European Myeloma Network B.V. | Completed | No outcome recorded |
| Phase 1/2 | NCT02057640 | May 2014 → May 2018 | plasma cell myeloma | Jason Valent | Completed | No outcome recorded |
| Phase 1/2 | NCT01946152 | Mar 2014 → Mar 2020 | plasma cell myeloma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT02004275 | Feb 2014 → Dec 2021 | plasma cell myeloma | Alliance for Clinical Trials in Oncology | Unknown | No outcome recorded |
| Phase 1/2 | NCT01979276 | Nov 2013 → Oct 2016 | plasma cell myeloma | Weill Medical College of Cornell University | Terminated | No outcome recorded |
| Phase 1/2 | NCT01857115 | Apr → Nov 2013 | plasma cell myeloma | European Myeloma Network B.V. | Completed | No outcome recorded |
| Phase 1/2 | NCT01754402 | Jan 2013 → Dec 2016 | plasma cell myeloma | Cristina Gasparetto | Unknown | No outcome recorded |
| Phase 1/2 | NCT02145715 | Jan 2013 → Jul 2015 | plasma cell myeloma | Prof Jamie Cavenagh | Unknown | No outcome recorded |
| Phase 1/2 | NCT01794520 | Oct 2012 → Nov 2021 | refractory plasma cell neoplasm | AbbVie | Completed | No outcome recorded |
| Phase 1/2 | NCT01592370 | Aug 2012 → Sep 2020 | Hodgkins lymphoma, non-Hodgkin lymphoma, plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT01246063 | May 2012 → Dec 2017 | plasma cell myeloma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT01522872 | Feb 2012 → Sep 2016 | plasma cell myeloma | Threshold Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT01541332 | Feb 2012 → Dec 2016 | plasma cell myeloma | Oncotherapeutics | Unknown | No outcome recorded |
| Phase 1/2 | NCT01389427 | Nov 2011 → May 2015 | mantle cell lymphoma | The Lymphoma Academic Research Organisation | Completed | No outcome recorded |
| Phase 1/2 | NCT01464034 | Nov 2011 → Jul 2020 | plasma cell myeloma | Criterium, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT01432600 | Nov 2011 → Aug 2016 | plasma cell myeloma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT01212952 | Sep 2011 → Aug 2017 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT01421186 | Jul 2011 → Aug 2020 | plasma cell myeloma | MorphoSys AG | Completed | No outcome recorded |
| Phase 1/2 | NCT01297764 | Apr 2011 → Jul 2026 overdue | plasma cell myeloma | Hackensack Meridian Health | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT01155583 | Jun 2010 → May 2016 | refractory plasma cell neoplasm | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01084252 | May 2010 → Dec 2018 | hematopoietic and lymphoid cell neoplasm | Sanofi | Completed | No outcome recorded |
| Phase 1/2 | NCT01221103 | Apr 2010 → Apr 2012 | mantle cell lymphoma | Southern Europe New Drug Organization | Unknown | No outcome recorded |
| Phase 1/2 | NCT01049945 | Feb 2010 → Nov 2012 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT01246557 | Dec 2009 → Apr 2014 | B-cell chronic lymphocytic leukemia | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT01029054 | Sep 2009 → Dec 2011 | plasma cell myeloma | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00966693 | Aug 2009 → Jul 2018 | plasma cell myeloma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00903968 | Jun 2009 → Jun 2016 | plasma cell myeloma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT00849251 | Nov 2008 → Dec 2011 | plasma cell myeloma | University of Washington | Terminated | No outcome recorded |
| Phase 1/2 | NCT00750815 | Sep 2008 → Dec 2012 | plasma cell myeloma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT00708292 | Jul 2008 → Jan 2011 | refractory plasma cell neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT00833833 | Jun 2008 → Apr 2011 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT00724568 | May 2008 → Apr 2009 | plasma cell myeloma | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00981708 | Feb 2008 → Jan 2011 | amyloidosis | University of Athens | Completed | No outcome recorded |
| Phase 1/2 | NCT00793923 | Jan 2008 → Jan 2012 | wet macular degeneration | Subhransu K. Ray, M.D., Ph.D. | Completed | No outcome recorded |
| Phase 1/2 | NCT00531284 | Sep 2007 → Oct 2014 | kidney cancer, non-small cell lung carcinoma, ovarian cancer, plasma cell myeloma +1 | Amgen | Completed | No outcome recorded |
| Phase 1/2 | NCT00378105 | Sep 2006 → Jul 2009 overdue | plasma cell myeloma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT00401011 | Aug 2006 → Dec 2010 | plasma cell myeloma | AEterna Zentaris | Completed | No outcome recorded |
| Phase 1/2 | NCT00384553 | Jun 2004 → Jun 2010 | non-Hodgkin lymphoma | University of Magdeburg | Unknown | No outcome recorded |
| Phase 1/2 | NCT00244153 | Jun 2004 → Aug 2007 | rheumatic disorder | Charite University, Berlin, Germany | Unknown | No outcome recorded |
| Phase 1/2 | NCT00274430 | Jul → Sep 2003 | high altitude pulmonary edema | University of Zurich | Completed | No outcome recorded |
| Phase 1/2 | NCT00308477 | — | macular retinal edema, occlusion of tributary of retinal vein | Sanwa Kagaku Kenkyusho Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT00308542 | — | diabetic macular edema | Sanwa Kagaku Kenkyusho Co., Ltd. | Completed | No outcome recorded |
| Phase 2629 trials | ||||||
| Phase 2 | NCT07605416 | Jul 2026 → Nov 2032 expected | plasma cell leukemia | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07588698 | Jul 2026 → Jul 2028 expected | diffuse large B-cell lymphoma | Mwanasha Merrill, MD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07698080 | Jul 2026 → Jul 2028 expected | aplastic anemia, leukemia, lymphoma, myelodysplastic syndrome +1 | Hematology department of the 920th hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06818981 | Jul 2026 → Jun 2027 expected | obstructive sleep apnea syndrome | Medical University of South Carolina | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06348147 | Jul 2026 → May 2027 | disease related to hematopoietic stem cell transplant, plasma cell myeloma | UNC Lineberger Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT07652879 | Jun 2026 → Jan 2028 expected | POEMS syndrome | Shanghai Changzheng Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07643103 | Jun 2026 → May 2028 expected | precursor B-cell acute lymphoblastic leukemia | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07604987 | May 2026 → May 2028 expected | primary central nervous system lymphoma | Zou Dehui | Recruiting | No outcome recorded |
| Phase 2 | NCT07567274 | May → Jul 2026 overdue | tinnitus | Leading Edge Clinic | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT07548736 | Apr 2026 → Apr 2027 expected | enterocolitis | Sixth Affiliated Hospital, Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Show all 629 trials opens the full record — a long page | ||||||
| Phase 2/345 trials | ||||||
| Phase 2/3 | NCT07095452 | Jan 2026 → Jan 2042 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07059156 | Jun 2025 → Jun 2027 expected | adult acute lymphoblastic leukemia | Shanxi Bethune Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07343128 | Jun → Dec 2025 | fibromyalgia | Sanliurfa Education and Research Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT06212336 | May 2025 → Jun 2027 expected | Lassa fever | Irrua Specialist Teaching Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06913374 | May 2025 → May 2026 overdue | primary thrombocytopenia | Shandong University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06879379 | Mar 2025 → Mar 2028 expected | plasma cell myeloma | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07290595 | Jan 2025 → Feb 2026 overdue | hypotensive disorder | Sahiwal medical college sahiwal | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06621329 | Oct 2024 → Jul 2026 overdue | headache disorder, subarachnoid hemorrhage | University of California, Davis | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06496997 | Aug 2024 → Aug 2025 overdue | acute respiratory distress syndrome | Fayoum University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07368075 | Jul 2024 → Oct 2025 | hypotensive disorder | Sahiwal medical college sahiwal | Completed | No outcome recorded |
| Phase 2/3 | NCT07590752 | Mar 2024 → Jun 2026 overdue | neuropathy, painful, substance-related disorder | Sahiwal medical college sahiwal | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05998317 | Oct → Nov 2023 | — | Mansoura University | Completed | No outcome recorded |
| Phase 2/3 | NCT05809011 | Apr 2023 → Nov 2025 | heart failure | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | Unknown | No outcome recorded |
| Phase 2/3 | NCT05665140 | Feb 2023 → Aug 2027 expected | plasma cell myeloma | University Hopsital Schleswig Holstein Campus Lübeck | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04452565 | Jun 2022 → Dec 2023 | severe acute respiratory syndrome | Biomed Industries, Inc. | Unknown | No outcome recorded |
| Phase 2/3 | NCT05752305 | Jan 2022 → Jul 2023 | — | University of Granada | Completed | No outcome recorded |
| Phase 2/3 | NCT05145543 | Dec 2021 → Mar 2022 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03692754 | Nov → Dec 2021 | autoimmune thrombocytopenia, thrombocytopenic purpura | Shandong University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05066997 | Oct 2021 → Apr 2026 | diabetic macular edema | Oculis | Completed | No outcome recorded |
| Phase 2/3 | NCT03874936 | Nov 2020 → Dec 2022 | developmental dysplasia of the hip | Odense University Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT04563559 | Nov 2020 → Nov 2021 | cataract, glaucoma | Duke University | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT04513639 | Aug 2020 → Jun 2031 expected | plasma cell myeloma | Oslo University Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02938468 | Sep 2016 → Sep 2021 | — | University of Calgary | Unknown | No outcome recorded |
| Phase 2/3 | NCT03531970 | Aug 2016 → Aug 2017 | — | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT02991339 | Jun 2016 → Dec 2017 | hyperbilirubinemia, liver disorder | Shanghai Zhongshan Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT02760043 | Apr 2016 → Oct 2018 | osteoarthritis | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 2/3 | NCT02751593 | Jan 2016 → Dec 2017 | autoimmune thrombocytopenia, pregnancy disorder | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT02491632 | Aug 2015 → Mar 2019 overdue | metastatic malignant neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02416388 | Jan 2015 → Jul 2025 overdue | acute myeloid leukemia | University Hospital, Angers | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02111785 | Mar 2014 → Dec 2017 | — | University of Virginia | Terminated | No outcome recorded |
| Phase 2/3 | NCT01442428 | Jan 2014 → Mar 2016 | HIV infectious disease, immune reconstitution inflammatory syndrome, tuberculosis | University of Minnesota | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT01790685 | Feb 2013 → Dec 2014 | retinal vein occlusion | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2/3 | NCT02552251 | Aug 2012 → Dec 2015 | classic congenital adrenal hyperplasia | University Hospital, Caen | Unknown | No outcome recorded |
| Phase 2/3 | NCT01523314 | Mar → Aug 2012 | diabetic macular edema | King Saud University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02836158 | Sep 2010 → Dec 2025 overdue | primary central nervous system lymphoma | Navy General Hospital, Beijing | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02657785 | Sep 2010 → Dec 2028 expected | primary central nervous system lymphoma | Navy General Hospital, Beijing | Recruiting | No outcome recorded |
| Phase 2/3 | NCT01273727 | Jun 2010 → Apr 2014 | macular retinal edema, preretinal fibrosis | Retina Specialists, PC | Completed | No outcome recorded |
| Phase 2/3 | NCT00861250 | Mar 2009 → Dec 2014 | plasma cell myeloma | Tampere University Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT00953303 | Jan 2009 → Sep 2011 | heart failure | Hebei Medical University | Completed | No outcome recorded |
| Phase 2/3 | NCT00333996 | May 2006 → Mar 2007 | anterior uveitis | Allergan | Terminated | No outcome recorded |
| Phase 2/3 | NCT00592566 | Jul 2003 → Oct 2006 | leptospirosis | Mahidol University | Terminated | No outcome recorded |
| Phase 2/3 | NCT00205751 | Aug 2001 → Oct 2009 | plasma cell myeloma | Austrian Forum Against Cancer | Completed | No outcome recorded |
| Phase 2/3 | NCT00127764 | Jan 2001 → Apr 2005 | pemphigus | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 2/3 | NCT00038090 | Jun 2000 → May 2005 | plasma cell myeloma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2/3 | NCT00002499 | Jan 1990 → ? | leukemia | Grupo Argentino de Tratamiento de la Leucemia Aguda | Unknown | No outcome recorded |
| Phase 3269 trials | ||||||
| Phase 3 | NCT07543458 | Oct 2026 → Jul 2030 expected | arbovirus infection, dengue disease, hemorrhagic fever | Oxford University Clinical Research Unit, Vietnam | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07674576 | Sep 2026 → Aug 2028 expected | — | CMC Ambroise Paré | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07576660 | Jul 2026 → Sep 2029 expected | acute respiratory distress syndrome | Southeast University, China | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07665762 | Jun 2026 → Sep 2028 expected | — | The University of Hong Kong | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07624513 | Jun 2026 → Oct 2033 expected | plasma cell myeloma | Dana-Farber Cancer Institute | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07413055 | Mar → Nov 2026 expected | — | Oman Ministry of Health | Recruiting | No outcome recorded |
| Phase 3 | NCT06511765 | Mar → Sep 2026 expected | lumbar disk disease | Elsan | Recruiting | No outcome recorded |
| Phase 3 | NCT07052201 | Feb 2026 → Jan 2028 expected | bronchopulmonary dysplasia | The Children's Hospital of Zhejiang University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07708142 | Jan 2026 → Jul 2027 expected | retinal vein occlusion | SANGMYUNG innovation | Recruiting | No outcome recorded |
| Phase 3 | NCT07222761 | Jan 2026 → May 2029 expected | refractory plasma cell neoplasm | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Show all 269 trials opens the full record — a long page | ||||||
| Phase 4323 trials | ||||||
| Phase 4 | NCT07605065 | Nov 2026 → Feb 2027 expected | headache disorder | Pak Emirates Military Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07614802 | Aug 2026 → Aug 2027 expected | — | Duke University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07064993 | Jul 2026 → Feb 2027 expected | — | Arzu Esen Tekeli | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07699744 | Jul 2026 → Jun 2027 expected | rotator cuff syndrome | Seoul National University Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07709884 | Jul 2026 → Dec 2028 expected | plasma cell myeloma | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07699315 | Jul → Dec 2026 expected | pulpitis | Watim Medical & Dental College | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07357597 | Jun 2026 → Jan 2028 expected | stomatitis | AstraZeneca | Recruiting | No outcome recorded |
| Phase 4 | NCT07554963 | May → Oct 2026 expected | impacted teeth, multiple | Hayat Abad Medical Complex, Peshawar | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07494136 | May 2026 → May 2027 expected | radiculopathy, sciatica | University of Miami | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07556952 | Apr 2026 → Mar 2028 expected | chronic pain syndrome | McGill University Health Centre/Research Institute of the McGill University Health Centre | Recruiting | No outcome recorded |
| Show all 323 trials opens the full record — a long page | ||||||
| Phase not applicable217 trials | ||||||
| — | NCT07435493 | Nov 2026 expected | adenoid hypertrophy, obstructive sleep apnea syndrome | Ain Shams University | Not yet recruiting | No outcome recorded |
| — | NCT07498998 | Jul → Aug 2026 overdue | carpal tunnel syndrome | Tanta University | Not yet recruiting | No outcome recorded |
| — | NCT07631910 | Jul → Oct 2026 expected | — | Sir Run Run Shaw Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07677215 | Jul 2026 → Sep 2027 expected | osteoarthritis, knee | Poznan University of Medical Sciences | Not yet recruiting | No outcome recorded |
| — | NCT07672873 | Jun → Dec 2026 expected | pulpitis | Marmara University | Recruiting | No outcome recorded |
| — | NCT07341854 | Jun 2026 → Jun 2027 expected | neuropathy, painful | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07550803 | Jun 2026 → Jun 2027 expected | sleep disorder | Seoul National University Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07584200 | Jun 2026 → Mar 2027 expected | osteoarthritis, hip | Poznan University of Medical Sciences | Not yet recruiting | No outcome recorded |
| — | NCT07607691 | Jun → Oct 2026 expected | bursitis, chronic pain syndrome, frozen shoulder, rotator cuff syndrome | Ankara City Hospital Bilkent | Not yet recruiting | No outcome recorded |
| — | NCT07525934 | Apr → Jul 2026 overdue | — | Recep Karakaşoğlu | Not yet recruiting | No outcome recorded |
| Show all 217 trials opens the full record — a long page | ||||||
| Phase not stated6 trials | ||||||
| — | NCT03969875 | Aug 2018 → Apr 2022 | osteoarthritis | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| — | NCT04534322 | — | refractory plasma cell neoplasm | Oncopeptides AB | Approved for marketing | No outcome recorded |
| — | NCT02856438 | — | plasma cell myeloma | Bristol-Myers Squibb | No longer available | No outcome recorded |
| — | NCT00517894 | — | lymphoma | Study Group of Medical Tumour Therapy (AGMT) | No longer available | No outcome recorded |
| — | NCT01250808 | — | plasma cell myeloma | Peking University | Available | No outcome recorded |
| — | NCT02368301 | — | plasma cell myeloma | Bristol-Myers Squibb | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 1,879 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 020 trials | ||||||
| Phase 0 | NCT07485127 Comparator | Feb → Aug 2026 overdue | — | Sohag University | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05287035 Comparator | Jul 2023 → Jan 2025 | — | University of Texas at Austin | Unknown | No outcome recorded |
| Phase 0 | NCT05687981 Comparator | Jan → Dec 2023 | — | Tanta University | Unknown | No outcome recorded |
| Phase 0 | NCT05305404 Comparator | Mar 2022 → Jun 2024 | alcohol dependence | Stony Brook University | Unknown | No outcome recorded |
| Phase 0 | NCT05142098 Comparator | Jan → Jul 2022 | — | Dow University of Health Sciences | Unknown | No outcome recorded |
| Phase 0 | NCT03979664 Comparator | Mar → Dec 2021 | psoriasis | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 0 | NCT04848259 Comparator | Jan → Jun 2021 | impacted teeth, multiple | Al-Azhar University | Completed | No outcome recorded |
| Phase 0 | NCT04776850 Background | Dec 2020 → Dec 2022 | beta-thalassemia major, sickle cell disease, sickle cell-beta plus-thalassemia, sickle cell-beta zero-thalassemia | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 0 | NCT04161248 Background | Sep 2020 → Dec 2026 expected | B-cell non-Hodgkin lymphoma | Canadian Cancer Trials Group | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04547842 Comparator | Sep 2020 → Jul 2023 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 0 | NCT03855059 Comparator | Jun 2019 → Apr 2020 | — | University of Arizona | Completed | No outcome recorded |
| Phase 0 | NCT01422733 Background | Jun → Jul 2018 | obesity disorder, polycystic ovary syndrome | University of Virginia | Withdrawn | No outcome recorded |
| Phase 0 | NCT03199482 Comparator | Jul → Oct 2017 | — | Cairo University | Unknown | No outcome recorded |
| Phase 0 | NCT03237533 Comparator | Jun → Dec 2017 | lichen planus, oral | University of Faisalabad | Unknown | No outcome recorded |
| Phase 0 | NCT02837614 Comparator | Oct 2015 → Jan 2016 | impacted teeth, multiple | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 0 | NCT01861340 Background | May 2014 → Apr 2016 | plasma cell myeloma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 0 | NCT01537861 Background | Jun 2012 → Feb 2014 | plasma cell myeloma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 0 | NCT01331590 Background | Jul 2011 → Oct 2014 | precursor lymphoblastic lymphoma/leukemia | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 0 | NCT01184885 Background | Jul 2010 → Mar 2011 | Burkitt lymphoma, acute lymphoblastic leukemia, adult T-cell leukemia/lymphoma, lymphoblastic lymphoma +1 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 0 | NCT01231009 Comparator | Jan 2010 → Jan 2012 | vestibular neuronitis | Aristotle University Of Thessaloniki | Unknown | No outcome recorded |
| Phase 1205 trials | ||||||
| Phase 1 | NCT07609706 Background | Oct 2026 → Aug 2031 expected | plasma cell myeloma | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07444710 Background | Aug 2026 → Sep 2027 expected | mantle cell lymphoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07608731 Background | Jun 2026 → Apr 2029 expected | diffuse large B-cell lymphoma of the central nervous system, large B-cell lymphoma | Allison Winter | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07082270 Background | Apr 2026 → Feb 2028 | plasma cell myeloma | Roswell Park Cancer Institute | Withdrawn | No outcome recorded |
| Phase 1 | NCT07380139 Comparator | Feb → Dec 2026 expected | — | Ain Shams University | Enrolling by invitation | No outcome recorded |
| Show all 205 trials opens the full record — a long page | ||||||
| Phase 1/2181 trials | ||||||
| Phase 1/2 | NCT06437054 Background | Dec 2026 | sensorineural hearing loss disorder, sudden hearing loss disorder | Seoul National University Hospital | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT07600151 Background | Dec 2026 → Sep 2036 expected | plasma cell myeloma | University Medical Center Hamburg-Eppendorf | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07175415 Background | Oct 2026 → Oct 2031 expected | T lymphoblastic leukemia/lymphoma, acute lymphoblastic leukemia | Princess Maxima Center for Pediatric Oncology | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07463807 Comparator | Jul → Aug 2026 overdue | plasma cell myeloma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07387926 Background | Jul 2026 → Sep 2033 expected | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), acute lymphoblastic leukemia | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Show all 181 trials opens the full record — a long page | ||||||
| Phase 2432 trials | ||||||
| Phase 2 | NCT07636564 Background | Oct 2026 → Apr 2031 expected | B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, acute leukemia of ambiguous lineage | SWOG Cancer Research Network | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07694089 Comparator | Oct 2026 → Aug 2029 expected | high grade astrocytic tumor | Akshitkumar MIstry | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06948084 Comparator | Aug 2026 → Feb 2028 expected | plasma cell myeloma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07709000 Background | Aug 2026 → Nov 2033 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07614360 Background | Aug 2026 → Feb 2029 expected | plasma cell myeloma | GlaxoSmithKline | Not yet recruiting | No outcome recorded |
| Show all 432 trials opens the full record — a long page | ||||||
| Phase 2/346 trials | ||||||
| Phase 2/3 | NCT07072585 Background | Aug 2026 → Sep 2035 expected | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | Children's Oncology Group | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07428369 Comparator | Jun 2026 → May 2038 | plasma cell myeloma | Regeneron Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT07570173 Background | May 2026 → Oct 2033 expected | B-cell acute lymphoblastic leukemia | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07542288 Comparator | Apr 2026 → Jun 2028 expected | metastatic malignant neoplasm in the brain | The Second Affiliated Hospital of Hainan Medical University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07185373 Background | Oct 2025 → Sep 2028 expected | primary central nervous system lymphoma | Huashan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07213375 Comparator | Sep 2025 → Oct 2026 expected | non-small cell lung carcinoma | Rigshospitalet, Denmark | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06616584 Background | May 2025 → Dec 2027 expected | non-small cell lung carcinoma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06768840 Comparator | Oct 2024 → Aug 2025 overdue | generalized vitiligo | South Valley University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06333834 Comparator | Jun 2024 → Nov 2025 | scorpion envenomation | Selene Guadalupe Huerta Olvera | Completed | No outcome recorded |
| Phase 2/3 | NCT05991388 Background | May 2024 → May 2031 expected | B-cell non-Hodgkin lymphoma | University of Birmingham | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06266481 Comparator | Mar → Apr 2024 | — | Pharos University in Alexandria | Unknown | No outcome recorded |
| Phase 2/3 | NCT05546359 Background | Jan 2024 → Jun 2025 | — | Acacia Pharma Ltd | Completed | No outcome recorded |
| Phase 2/3 | NCT06166108 Comparator | Dec 2023 → Nov 2024 | — | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03759093 Background | Sep 2023 → Sep 2025 | plasma cell myeloma | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 2/3 | NCT05553496 Comparator | Sep 2022 → Apr 2023 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05367271 Comparator | Aug 2022 → Sep 2024 | plantar fasciitis | Western Institute for Veterans Research | Completed | No outcome recorded |
| Phase 2/3 | NCT05096663 Comparator | Mar 2022 → Jun 2027 expected | non-small cell lung carcinoma | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04862585 Comparator | Oct 2021 → Jun 2024 | breast carcinoma in situ, female breast carcinoma | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2/3 | NCT04392999 Comparator | Feb 2021 → Mar 2023 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 2/3 | NCT04442022 Background | Sep 2020 → Dec 2026 expected | diffuse large B-cell lymphoma | Karyopharm Therapeutics Inc | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04061512 Comparator | Feb 2020 → Mar 2030 expected | Waldenstrom macroglobulinemia | University College, London | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04027322 Comparator | Jun 2019 → May 2022 | acute pharyngitis | Oman Medical Speciality Board | Completed | No outcome recorded |
| Phase 2/3 | NCT03863977 Comparator | Mar → Dec 2019 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT03367988 Background | Dec 2018 → Jan 2023 | drug dependence | University of South Florida | Unknown | No outcome recorded |
| Phase 2/3 | NCT03668639 Background | Sep 2018 → Mar 2023 | cervical cancer, chemotherapy-induced toxicity | Christina Ruhlmann | Unknown | No outcome recorded |
| Phase 2/3 | NCT03117751 Background | Mar 2017 → Sep 2026 expected | lymphoblastic leukemia, acute, with lymphomatous features | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT03021772 Comparator | Jan 2017 → Sep 2018 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT02914054 Comparator | Oct 2016 → Sep 2017 | autoimmune thrombocytopenic purpura, glucocorticoid therapy, response to | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT03098420 Comparator | Jul 2016 → May 2021 | — | University of Alabama at Birmingham | Terminated | No outcome recorded |
| Phase 2/3 | NCT03564704 Background | Feb 2016 → May 2021 | T-cell leukemia, adult acute lymphoblastic leukemia, lymphoblastic lymphoma | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03553238 Background | Feb 2016 → May 2020 | T lymphoblastic leukemia/lymphoma, T-cell leukemia, acute leukemia | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02945527 Comparator | Dec 2015 → Dec 2018 | cysticercosis | Universidad Peruana Cayetano Heredia | Terminated | No outcome recorded |
| Phase 2/3 | NCT03606369 Background | Nov 2015 → Jul 2018 | breast neoplasm | National Cancer Institute of Mexico | Unknown | No outcome recorded |
| Phase 2/3 | NCT02529774 Background | Sep 2015 → Sep 2020 | metastasis from malignant tumor of colon | Ye Xu | Unknown | No outcome recorded |
| Phase 2/3 | NCT02525848 Comparator | Aug 2015 → Mar 2016 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT02419118 Background | Jan → Oct 2015 | plasma cell myeloma | Vejle Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT02169882 Background | Dec 2014 → Nov 2016 | meningeal tuberculosis | Padjadjaran University | Completed | No outcome recorded |
| Phase 2/3 | NCT01805557 Background | Feb 2013 → Mar 2019 | diffuse large B-cell lymphoma | Fondazione Italiana Linfomi - ETS | Completed | No outcome recorded |
| Phase 2/3 | NCT01295112 Comparator | May 2011 → Oct 2015 | central retinal vein occlusion | Texas Retina Associates | Completed | No outcome recorded |
| Phase 2/3 | NCT01297686 Comparator | May 2011 → Feb 2012 | plantar fasciitis | University of British Columbia | Completed | No outcome recorded |
| Phase 2/3 | NCT01228331 Comparator | Oct 2010 → Dec 2019 | leukemia | University Medical Center Hamburg-Eppendorf | Completed | No outcome recorded |
| Phase 2/3 | NCT00720109 Background | Jul 2008 → Dec 2014 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), acute lymphoblastic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2/3 | NCT00934739 Comparator | Jun 2007 → Dec 2012 | oral cavity cancer | National Health Research Institutes, Taiwan | Terminated | No outcome recorded |
| Phase 2/3 | NCT00630565 Background | Jul 2006 → Jul 2022 | leukemia | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 2/3 | NCT00333814 Comparator | May 2006 → Dec 2008 | intermediate uveitis, posterior uveitis | Allergan | Completed | No outcome recorded |
| Phase 2/3 | NCT00199108 Background | Apr 2004 → Jun 2008 | adult acute lymphoblastic leukemia | Goethe University | Completed | No outcome recorded |
| Phase 3441 trials | ||||||
| Phase 3 | NCT07709715 Comparator | Jan 2027 → Dec 2028 expected | AL amyloidosis | Nexcella Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07665450 Comparator | Sep 2026 → Sep 2030 expected | plasma cell myeloma | Janssen Research & Development, LLC | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06980727 Comparator | Aug 2026 → Dec 2027 expected | urinary tract obstruction | University of Monastir | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07579351 Comparator | Aug 2026 → Jul 2028 expected | sciatica | Semnur Pharmaceuticals, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07678229 Comparator | Jul 2026 → Dec 2031 expected | mature T-cell and NK-cell non-Hodgkin lymphoma | Rong Tao | Not yet recruiting | No outcome recorded |
| Show all 441 trials opens the full record — a long page | ||||||
| Phase 4313 trials | ||||||
| Phase 4 | NCT07097493 Comparator | Aug → Dec 2026 expected | osteoarthritis, knee | Wake Forest University Health Sciences | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07228052 Comparator | Jul → Dec 2026 expected | asthma | Montefiore Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07639723 Background | Jul 2026 → Jul 2027 expected | — | Endeavor Health | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07638527 Comparator | Jul 2026 → Feb 2027 expected | — | Faisalabad Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07469488 Background | Apr 2026 → Aug 2029 expected | non-small cell lung carcinoma, toxic dermatosis, venous thromboembolism | Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting | No outcome recorded |
| Show all 313 trials opens the full record — a long page | ||||||
| Phase not applicable239 trials | ||||||
| — | NCT07454226 Background | May 2026 → Mar 2028 expected | acute lymphoblastic leukemia, phosphohydroxylysinuria | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| — | NCT07581470 Comparator | May 2026 → Jun 2027 expected | osteoarthritis, hip | Poznan University of Medical Sciences | Recruiting | No outcome recorded |
| — | NCT07558226 Comparator | May 2026 → Nov 2027 expected | — | Fundacio Puigvert | Recruiting | No outcome recorded |
| — | NCT07442890 Background | Apr 2026 → Apr 2028 expected | lung cancer | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07509866 Comparator | Apr → Oct 2026 expected | — | Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Show all 239 trials opens the full record — a long page | ||||||
| Phase not stated2 trials | ||||||
| — | NCT03763370 Background | — | plasma cell myeloma | GlaxoSmithKline | Available | No outcome recorded |
| — | NCT02666209 Background | — | plasma cell myeloma | Dana-Farber Cancer Institute | No longer available | No outcome recorded |
Press releases naming this drug 12 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-12-01 | Amgen | FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and dexamethasone For Patients With Multiple Myeloma At First Or Subsequent Relapse amgen.com ↗ |
| 2021-03-31 | Sanofi | FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma sanofi.com ↗ |
| 2021-02-26 | Sanofi | Media Update: CHMP recommends approval of Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for the treatment of relapsed multiple myeloma sanofi.com ↗ |
| 2020-08-20 | Amgen | FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX® (daratumumab) And Dexamethasone In Both Once- And Twice-Weekly Dosing Regimens amgen.com ↗ |
| 2018-10-01 | Amgen | FDA Approves KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma amgen.com ↗ |
| 2018-08-27 | Amgen | Amgen Submits Supplemental New Drug Application For KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone amgen.com ↗ |
| 2018-06-08 | Amgen | European Commission Approves Prolia® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis amgen.com ↗ |
| 2018-05-21 | Amgen | FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis amgen.com ↗ |
| 2018-04-27 | Amgen | Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia® (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis amgen.com ↗ |
| 2017-10-09 | Amgen | FDA Accepts Supplemental Biologics License Application For Prolia® (Denosumab) In Glucocorticoid-Induced Osteoporosis amgen.com ↗ |
| 2017-07-31 | Amgen | Amgen Submits Supplemental Biologics License Application For Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis amgen.com ↗ |
| 2016-08-29 | Amgen | Amgen Announces Positive Top-Line Results From Phase 3 Study Of Prolia® (Denosumab) In Patients Receiving Glucocorticoid Therapy amgen.com ↗ |
Evidence & citations 110 cited values
Every value below carries the sentence it was read from. 3,642 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dexamethasone | “including but not limited to DHAP (dexamethasone, cisplatin, high-dose cytarabine), ESHAP (etoposide, methylprednisolone, high-dose cytarabine and cisplatin), DICE...” NCT04486391 ↗3500“Standard Induction chemotherapy care included: vincristine, doxorubicin, and dexamethasone (VAD) (0.5 mg, 10 mg/m2, and 40 mg, respectively);dexamethasone,...” NCT00577096 ↗ “The study aims to evaluate the efficacy and safety of the quadruplet regimen Isatuximab in combination with Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRD) compared to...” NCT07334535 ↗ “This is a randomized, controlled study to assess the safety and effectiveness of treatment with an intracanalicular dexamethasone (0.4mg) insert when utilized in conjunction...” NCT05665270 ↗ “Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane Ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon...” NCT05331859 ↗ “Recommended rescue medications include tocilizumab for treatment of cytokine release syndrome (CRS); dexamethasone, acetaminophen, and diphenhydramine for CRS/infusion-related...” NCT07227597 ↗ “This is a randomized phase III trial of CC-5013 (lenalidomide, NSC-703813) and low dose dexamethasone (LLD) versus bortezomib (PS-341, NSC-681239), lenalidomide and low dose...” NCT01530594 ↗ “OZURDEX® (DEX implant, 0.7 mg) is a micro-ionized and non-preserved dexamethasone within a cylindrically-shaped 0.45 mm diameter x 6.5 mm length biodegradable Poly D,...” NCT03629210 ↗ “Patients randomized to receive corticosteroids will receive dexamethasone 20mg daily for 5 days and then 10mg for an additional 5 days, for a total of 10 days from the time of...” NCT05440851 ↗ “The medical intervention consists of intravenous dexamethasone (10 mg if bodyweight \< 70 kilograms, 20 mg if bodyweight \> 70 kilograms), intravenous cefazolin 2 grams,...” NCT04998513 ↗ “The purpose of this study is to find out what the response is and the side effects are with chemotherapy using a combination of drugs called D.T. PACE (Dexamethasone,...” NCT00107614 ↗ “The purpose of this study is to find out whether Tec-RVd (teclistamab, lenalidomide, bortezomib, and dexamethasone) after 3 treatment Cycles of Dara-RVd (daratumumab,...” NCT07099391 ↗ “Thirty-three newly diagnosed, symptomatic patients with MM received bortezomib 1.3 mg/m(2) intravenously on days 1, 4, 8 and 11, cyclophosphamide 300 mg/m(2) orally on days 1,...” PMID 19225538 ↗ Feb 2009 “Before the use of utidelone, all patients will accept pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration, and dexamethasone10 mg and...” NCT05866510 ↗ “One hundred and twenty four patients received one of the three IANB injections before the endodontic treatment: 2% lidocaine with 1:80 000 epinephrine; 2% lidocaine with 1:80...” NCT05361291 ↗ “After enrollment and randomization, patients assigned to corticosteroid therapy will receive it as a single-bolus intravenous injection of dexamethasone 20 mg (day 1), followed...” NCT05809011 ↗ “USG with a 25G needle, Bupivacaine 0.5% 30ml with 4mg preservative free dexamethasone divided as follows into the following 5 nerves: Posterior Tibial nerve (10ml), Saphenous...” NCT05368012 ↗ “R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion...” NCT02657785 ↗ “Patients will receive APG-2575 at target dose once daily for 28 days plus pomalidomide (4 mg ) on Days 1 through 21 and dexamethasone (40 mg for patients ≤ 75 years old or 20...” NCT04942067 ↗ “rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab...” NCT00581854 ↗ “R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in...” NCT02836158 ↗ “Patients with a persistently positive interim-PET scan assigned to arm B2 will receive six blocks of the B-ALL protocol (rituximab, methotrexate, ifosfamide, etoposide,...” NCT00554164 ↗ “Recommended rescue medications are pegfilgrastim or equivalent, histamine-1 (H1) receptor antagonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent,...” NCT07419295 ↗ “Epidural steroid injectate will be 2cc of 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120...” NCT01238536 ↗ “Opioid-Free Multimodal Analgesia will receive preoperative acetaminophen (15 mg/kg) and ibuprofen (10 mg/kg), intraoperative ketamine (0.5 mg/kg IV) and dexamethasone (0.1...” NCT07435493 ↗ “The investigator prospectively evaluated the combination of Rituximab and Dexa-BEAM (dexamethasone, carmustine, etoposide, cytarabine, melphalan) followed by high dose therapy...” NCT02099292 ↗ “The purpose of this study is to evaluate the efficacy and safety of NXC-201 compared with Dara-CyBorD (daratumumab-cyclophosphamide-bortezomib-dexamethasone) in the treatment...” NCT07709715 ↗ “Patient eligible to enter the study will receive 9 to 12 cycles (according to response) of intravenous Isatuximab (10 mg/kg) and oral Pomalidomide 4 mg from day 1 to day 21 and...” NCT05066607 ↗ “Participants instructed to instill 1 drop of SHP640 (Povidone-iodine \[PVP-I\] 0.6 percent \[%\] and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID)...” NCT02998554 ↗ “1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone...” NCT03279796 ↗ “Intraoperative time: intravenous ketamine 0.5 mg kg-1, intravenous dexamethasone 8 mg Postoperative time: paracetamol 1 g every 6 hours a day, nefopam 20 every 8 hours a day,...” NCT06381063 ↗ “Patients were treated by Azacytidine(75 mg/m2 on days 1-7) plus CAOLD regimen (cyclophosphamide 400mg/m2 qd d1; cytarabine 30mg/m2 qd d1-d4; vindesine 2mg/m2 qd d1;...” NCT06176027 ↗ “Induction therapy consist of bortezomib, lenalidomide, and dexamethasone (VRd) or daratumumab, lenalidomide, and dexamethasone (DRd) or daratumumab, bortezomib, lenalidomide,...” NCT07149857 ↗ “Pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration, and dexamethasone10 mg and cimetidine 300 mg by intravenous injection 30 minutes prior to...” NCT05673590 ↗ “Initially Dexamethasone 6x per day for 2 weeks followed by 4x per day for one month, 3x per day for one month, 2x per day for one month, and finally 1x per day for one month -...” NCT01682421 ↗ “This study will investigate the efficacy and safety of OZURDEX® (dexamethasone intravitreal implants; DEX, Allergan, Inc. Irvine, CA) as monotherapy for the treatment of...” NCT05101928 ↗ “This prospective, single-center, open-label, investigator-sponsored clinical study seeks to investigate the outcomes of patients undergoing vitro-retinal surgery with the...” NCT04462523 ↗ “For relapsed refractory MCL patients who had received BTK inhibitors: selinexor 60mg once daily on days 1 and 8, zuberitamab 375 mg/m² on day 0, Dexamethasone 20 mg on days 1-3...” NCT07264894 ↗ “Adjunctive corticosteroids to be dosed at 0.4mg/kg/day of dexamethasone or equivalent for week 1, then 0.3mg/kg/day for week 2, 0.2mg/kg/day for week 3, 0.1mg/kg/day for week...” NCT06446245 ↗ “Once the patient has started the study treatment, the dose of corticosteroids will be tapered every 5 days (e.g., dexamethasone 2 mg or prednisone 15 mg per taper), as...” NCT02490878 ↗ “R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) administered in 3 week cycles for 3 cycles R-HAD (rituximab, cytarabine, dexamethasone) administered...” NCT01865110 ↗ “In addition, dexamethasone, a drug used to prevent nausea and vomiting in chemotherapy patients that may have protective effects on the liver, will be administered to patients...” NCT01273480 ↗ “Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2...” NCT01667302 ↗ “To determine patient preference and treatment outcomes with an intracanalicular dexamethasone (0.4mg) insert compared to standard steroid drop regimen in the contralateral eye...” NCT04396990 ↗ “Comparing the Effects of Ondansetron Versus Dexamethasone on the Incidence of Post-dural Puncture Headache (PDPH) , Nausea and Vomiting After Spinal Anaesthesia of Parturients...” NCT05202574 ↗ “DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2...” NCT01014208 ↗ “Placebo, given orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1)...” NCT01052844 ↗ “R-HCVAD - Rituximab (375 mg/m2), Cyclophosphamide (300 mg/m2), Mesna (600 mg/m2), Doxorubicin (50 mg/m2), Vincristine (2 mg total), Dexamethasone (40 mg total), Methotrexate...” NCT01854372 ↗ “Dexamethasone, a potent synthetic glucocorticoid with minimal mineralocorticoid effects, is commonly administered as an anesthesia adjunct for the prevention of postoperative...” NCT02112422 ↗ “Patients receive concurrent aprepitant 125mg, dexamethasone 12mg, and ondansetron 8mg p.o. on day1. AND then patients received aprepitant 80mg, dexamethasone 8mg on day 2-5 at...” NCT03572829 ↗ “Participants are required to receive prophylactic mouthwash (steroid mouthwash \[dexamethasone or equivalent\] is highly recommended) to mitigate the onset and severity of...” NCT06356311 ↗ “This study will compare the efficacy and safety of low dose chidamide combined with high-dose dexamethasone versus high-dose dexamethasone monotherapy in adults with primary...” NCT05411874 ↗ “with varied cycles, including Daunorubicin, Vincristine, Prednisone, Pegaspargase, Rituximab, Cytarabine, Mercaptopurine, Cyclophosphamide, Methotrexate, Doxorubicin,...” NCT04845035 ↗ “Patients would receive a single intravenous infusion of HR20013 (Day 1) before cisplatin-based chemotherapy, alongside oral dexamethasone (Day 1, 12 mg, once a day; Day 2-4,...” PMID 40866861 ↗ Aug 2025 “Used drugs are rituximab,cyclophosphamide, prednisone, dexamethasone, vincristine, methotrexate, iphosphamide, teniposide, etoposide, dexamethasone, cytarabine,adriamycin,...” NCT01290120 ↗ “Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle...” NCT01389427 ↗ “Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in...” NCT02573935 ↗ “This trial is to evaluate the efficacy of concurrent chemoradiotherapy with cisplatin followed by VIPD (etoposide, ifosfamide, cisplatin, dexamethasone) in localized NK/T-cell...” NCT00418535 ↗ “cyclophosphamide, anthracene nucleus chemotherapeutics(doxorubicin,liposomal doxorubicin, etc.), vinca alkaloids(vincristine, vindesine, etc.),and glucocorticoid...” NCT05498259 ↗ “Chemotherapy is DHAOx at days 71, 113 and 155 (oxaliplatin (130 mg/m2, day 1) and cytarabine (ARA-C, 2x 1000 mg/m2 at day 2) dexamethasone PO (40 mg/m2, day 1)), as per...” NCT02042391 ↗ “Day 1: Aprepitant 125mg QD (once daily); Ondansetron 8mg BD (twice daily); Dexamethasone 12mg QD (Aprepitant, Ondansetron and Dexamethasone to be take 60 minutes before...” NCT07455955 ↗ “induction therapy using the combination of dexamethasone, lenalidomide (revlimid), daratumumab (Darzalex) and carfilzomib (Kyprolis) to treat patients with newly diagnosed...” NCT03224507 ↗ “Chemotherapy agents for reinduction include vincristine, dexamethasone, polyethylene glycol (PEG)-asparaginase (Erwinia asparaginase when PEG-asparaginase is not available),...” NCT04501614 ↗ “Patients will receive a 5mL injection comprised of 4.5mL 1% bupivacaine and 0.5mL of dexamethasone (10mg/mL) directed towards the sphenopalatine ganglion on each side (5 mL on...” NCT04331938 ↗ “Rituximab combined with Chemotherapy (Rituximab, Cyclophosphamide, doxorubicin, Vincristine, Prednisone, Ifosfamide, Gemcitabine, cisplatin, Carboplatin, Etoposide, MESNA,...” NCT07187960 ↗ “Dexalgen® will be administered at a dose equivalent to dexamethasone 1.5 mg, dipyrone 500 mg, and hydroxocobalamin 5 mg (one ampoule for each type) a day at a single intramuscular dose” NCT01147289 ↗ “Intravenous administration of paracetamol 1 g, morphine 0.1 mg/kg, dexamethasone 8 mg, and ketamine 0.5 mg/kg bolus followed by 0.3 mg/kg/h infusion for postoperative pain management.” NCT07455565 ↗ “intravenous dexamethasone at a dose of 10 mg 30 minutes prior to chemotherapy on Day 1, followed by intravenous dexamethasone at a dose of 8 mg on days 2, 3, and 4 post-chemotherapy.” NCT06314906 ↗ “The purpose of this study is to determine whether an intravitreal dexamethasone implant (Ozurdex, Allergan) is effective to manage macular edema secondary to non-infectious uveitis.” NCT01870440 ↗ “Prednisone/prednisolone 5 mg tablet orally twice daily/dexamethasone 0.5 mg tablet orally once daily continuously in 28-day cycle up to disease progression, death, or end of study.” NCT00474383 ↗ “Phase II Clinical Study of Daratumumab Combined With Bortezomib, Lenalidomide and Dexamethasone (DVRd) in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma” NCT06158269 ↗ “ZR2:Rituximab 375mg/m2, D1, Lenalidomide 24mg qd D1-14, zebutinib 160mg bid RDHAP:Rituximab 375mg/m2 D0, dexamethasone 40mg D1-4, cytarabine 2g/m2 q12h D2, cisplatin 25mg/m2 D1-3.” NCT05992597 ↗ “Intravenous administration of Actovegin, vitamins B1, B6, B12, C, oxytocin/dexamethasone, calcium gluconate, etc in 250 ml normal saline administered during approximately 2 hours” NCT03543917 ↗ “Thalidomide, day 1 cycle 1, 100 mg/24 h. oral, in combination with cyclophosphamide and dexamethasone. If toxicity is <Grade 2, dose should be increased to 200 mg/24 h. in day 15” NCT00652041 ↗ “compare the effectiveness of supra periosteal injection of dexamethasone versus placebo in reducing post operative pain in teeth diagnosed with symptomatic irreversible pulpitis” NCT07233564 ↗ “Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)” NCT03964090 ↗ “Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, dexamethasone (Phapros) 2x5 mg iv will be given with interval 8 hour, within the IBU-PCT-DEX intervention.” NCT06604598 ↗ “Dexamethasone will be administered on the days of isatuximab administration and can be discontinued after two cycles of therapy, or continued at discretion of investigator.” NCT06517017 ↗ “After removal of thyroid gland, 8mg of dexamethasone will be diluted in 100cc of irrigation water and irrigate the operative field for 1 minute for the intervention group.” NCT07068048 ↗ “A strip of neomycin sulfate, polymyxin B sulfate, and dexamethasone ophthalmic ointment will be then applied into the lower conjunctival fornix to patients in both groups.” NCT02424357 ↗ “Patients randomized to receive an ONB will receive the block with dexamethasone 2mg (steroid) each site with 3ml 1% lidocaine (local anesthetic), for a total of two sites.” NCT03007420 ↗ “10mg of dexamethasone (1cc) mixed with 1cc of 2% preservative-free xylocaine (lidocaine) will be injected on each side of the stenotic segment under fluoroscopic guidance” NCT01995461 ↗ “azacitidine S.C 25 mg/m2 D1,2,3,4,5 rituximab I.V. 375 mg/m2 D8 gemcitabine I.V. 1,000 mg/m2, D8,15 dexamethasone I.V. or P.O. 40 mg D8,9,10,11 cisplatin 70 mg/m2 I.V. D8” NCT03719989 ↗ “Gemcitabine 1.0 g/m² on day 1, etoposide 60 mg/m² on days 1-3, pegaspargase 2000 IU/m² on day 4, and dexamethasone 40 mg on days 1-4, repeated every 21 days for 1 cycle.” NCT07678229 ↗ “The primary objective is to assess the efficacy and safety of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (Dara-VRD) followed by cilta-cel in high-risk SMM.” NCT06574126 ↗ “single intratympanic injection of either 12 mg OTO-104 (otic formulation of dexamethasone in thermosensitive poloxamer) or placebo (1:1) and were observed for 3 months.” PMID 37185596 ↗ Apr 2023 “Induction: Lenalidomide 25 mg daily on Days 1-21 followed by 7 day rest and Dexamethasone 40 mg by mouth (po) daily on Days 1, 8, 15 and 22 every 28 days for 4 cycles.” NCT00691704 ↗ “Multi-agent chemotherapy including vincristine, prednisone, daunorubicin, cyclophosphamide, pegaspargase, cytarabine, 6-MP, MTX, and dexamethasone per protocol phases.” NCT07454226 ↗ “Dexamethasone sodium phosphate, 0.1% ophthalmic solution will be administered 4 times daily for 4 weeks, then 2 times daily for 2 weeks, then 1 time daily for 2 weeks.” NCT06213649 ↗ “VRD:Bortezomib, Lenalidomide and Dexamethasone Bortezomib SC 1.3mg/sqm on day 1,8,15,22, Lenalidomide oral 25 mg on day 1-21, and Dexamethasone 40mg on day 1,8,15,22” NCT05870917 ↗ “Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion.” NCT01576588 ↗ “Use of a dexamethasone insert alleviates the need for postoperative steroid eye drops and may provide increased pain relief post-CXL as compared to topical therapy.” NCT04168112 ↗ “Gemox: Gemcitabine and Oxaliplatin; IGEV: Ifosfamide, Gemcitabine, Vinorelbine, and Prednisolone; DHAP: Dexamethasone, high-dose Cytarabine (Ara-C) and Cisplatin.” NCT04342936 ↗ “Dexamethasone, although potentially protective against perioperative dysphagia and airway compromise, could inhibit fusion, a generally proinflammatory process.” PMID 25932600 ↗ May 2015 “Next, an anesthetic solution of Ropivacaine 0.375% (dose 37.5 mg) plus Mepivacaine 1% (dose 100 mg) and Dexamethasone 4mg, total volume 21 ml, will be injected.” NCT06155903 ↗ “This phase 1/2 dose-escalation study aimed to determine the maximum tolerated dose (MTD) of lenalidomide in combination with melphalan and dexamethasone (M-dex)” PMID 20724537 ↗ Aug 2010 “Palonosetron 0.25 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV for early emesis and for delayed emesis Dexamethasone 8 mg orally on days 2, 3 and 4.” NCT03606369 ↗ “5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are supplied from the first day of chemotherapy, and lasting for 3-5 days.” NCT02195908 ↗ “Steroid active group will involve two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day.” NCT02950233 ↗ “Lumbar puncture: cytarabine 50mg+dexamethasone 5mg+methotrexate 10mg, intrathecal injection, once a month after remission, a total of 4-6 courses of treatment.” NCT06861348 ↗ “Intraoperatively: Intravenous Dexamethasone 0.1mg/kg (maximum dose of 8mg), Magnesium 2g, Acetaminophen 1000mg, and local infiltration of 0.5% Ropivacaine 20ml” NCT07076069 ↗ “Group A will receive 0.07 mg/cm of 0.5% Hyperbaric Bupivacaine in conjunction with 2 mg (0.5 ml) of preservative-free Dexamethasone administered intrathecally” NCT07363941 ↗ “PD-1 monoclonal antibody is a new attempt treatment, and ruxolitinib and/or low-dose dexamethasone can reduce the inflammation that occur in EBV-HLH or CAEBV.” NCT05039580 ↗ “5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron , Tropisetron)and dexamethasone are supplied from the first day of chemtherapy,and lasting for 3-5days.” NCT02195921 ↗ “Combined Proteasome and Autophagy Inhibition in Relapsed/Refractory Multiple Myeloma-A Phase I Trial of Hydroxychloroquine, Carfilzomib, and Dexamethasone.” PMID 39866949 ↗ Jan 2025 “Methylene blue compound injection are mixed by Methylene Blue injection, Dexamethasone powder-injection, Ropivacaine injection and Normal saline injection.” NCT03200808 ↗ “Intra-arterial administration of argatroban (0.2-0.3 mg/min), dexamethasone (0.1 mg/min) and edaravone (0.3 mg/min) for 30 to 60 minutes after thrombectomy” NCT04202549 ↗ “Bortezomib-containing chemotherapy regimen (e.g. cyclophosphamide, bortezomib, and dexamethasone (CyBorD)) according to the institutional standard of care” NCT04973137 ↗ “10mg morphine + 8mg dexamethasone completed to 5 ml with normal saline + 10 ml of 0.25% bupivacaine (total volume of 15ml) were injected intra-articularly” NCT04790292 ↗ “After enrollment, patients are to receive four cycles of RAD induction treatment: a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone.” NCT00925821 ↗ “Standard Chemotherapy (which includes cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, 6-mercaptopurine, etoposide, and cytarabine” NCT03319901 ↗ “The most common drug used with iontophoresis for pain caused by such things as apophysitis of the knee is dexamethasone sodium phosphate (dexamethasone).” NCT03606980 ↗ “Includes vincristine, daunorubicin, cyclophosphamide, pegaspargase, prednisone, dexamethasone, cytarabine, 6-mercaptopurine, and high-dose methotrexate.” NCT07495631 ↗ “standard of care combined with glucocorticoid(dexamethasone: 3mg qd x 5 days; or prednisone: 20mg qd x 5 days; or methylprednisolone: 16mg qd x 5 days)” NCT05855395 ↗ “Dexamethasone 5mg and palonosetron 0.25mg i.v. will be given after induction, and droperidol 1.25 mg i.v. will be given during the abdominal closure.” NCT07480785 ↗ “Dextenza is a sustained-release dexamethasone intracanalicular insert recently approved by the FDA for pain and inflammation post ophthalmic surgery.” NCT04426734 ↗ “Patient will receive Dara-CyBorD (Daratumumab, Bortezomib, Cyclophosphamide, Dexamethasone) for at least 6 cycles, and then Daratumumab maintainance.” NCT06418477 ↗ “For treatment delivery, subjects will receive 60 mL of 0.25 percent ropivacaine with 4 mg of dexamethasone either at the initiation of the procedure” NCT05753046 ↗ “participants will receive the medications of Serivteronel and Dexamethasone (also known as SEVI-D) by oral tablets continuously per cycle (4 weeks).” NCT03600467 ↗ “Antihistamine, H2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) administered per product label prior to MK-6837.” NCT06460961 ↗ “Evaluate the efficacy and safety of Belantamab Mafodotin, cyclophosphamide, and dexamethasone in patients with Relapsed/Refractory Multiple Myeloma” NCT04896658 ↗ “20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block” NCT03887650 ↗ “usual paclitaxel pre-treatment consisting of Dexamethasone, Chlorpheniramine and ranitidine, at 15 and 1 day before the actual paclitaxel treatment” NCT03301454 ↗ “mLDG (lidocaine 0.16mg/mL, dexamethasone 0.02mg/mL, and gentamycin 0.16mg/mL) dissolved in 0.9% saline solution was administered three times a day.” NCT02577393 ↗ “Patients will be randamized allocated into two groups: Group D (Ondanesterone plus dexamethasone) or Group M (ondanesterone plus metoclopramide) .” NCT06810531 ↗ “FTD regimen(fotemustine, temozolomide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,temozolomide 150mg/m2 d1-5 po,dexamethasone 40mg d1-5 ivgtt” NCT05274139 ↗ “pre-treatment with Dexamethasone will induce a persistent senescence phenotype in tumor cell sub-populations expressing moderate/high levels of GR” NCT04037462 ↗ “0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.” NCT03493061 ↗ “0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.” NCT03678428 ↗ “intraligamentary dexamethasone administered prior to buccal 4% articaine infiltration in mandibular molars with symptomatic irreversible pulpitis” NCT07506265 ↗ “FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.” NCT01960192 ↗ “Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM” NCT06255847 ↗ “0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump” NCT02102789 ↗ “The patients will receive Dexamethasone 8 mg (Corodex, Laboratorio Celsius, Montevideo, Uruguay) PO 1 hour before surgery (Almeida et al 2019)” NCT05924191 ↗ “Intrathecal liposomal cytarabine combined with intrathecal prednisolone and oral dexamethasone during maintenance treatment for high-risk ALL” NCT00991744 ↗ “Dexamethasone 20 mg days 1-2, 4-5, 8-9 and 11-12 during the first 2 cycles, thereafter individualized dose depending on response and toxicity” NCT00602511 ↗ “The subject's standard care regimen upon entering the study; this could consist of hydrocortisone, dexamethasone, prednisone or prednisolone.” NCT03532022 ↗ “Oral mini-pulse steroids (low-dose dexamethasone: 5mg/week on 2 successive days per week) for 4 weeks before NCES and for 4 weeks afterward.” NCT07472816 ↗ “Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients” NCT04025450 ↗ “Lumbar Transforaminal Epidural Steroid Injections was administered, consisting of 4 mg dexamethasone and 0.33% lidocaine in a 3 ml solution” NCT06656429 ↗ “Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).” NCT00786851 ↗ “Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO.” NCT05230654 ↗ “Intervention group will receive 30 ml of a 50/50 mixture of isobaric bupivacaine 0.5% and lidocaine 1%, containing 8 mg of dexamethasone.” NCT07313553 ↗ “steroid therapy with Dexaven 4 mg / 1 ml - 2 injections at weekly intervals containing single doses of dexamethasone (total dose of 8 mg)” NCT04492774 ↗ “Dexamethasone: (oral) 40mg on Day 1,8,15,22 every month for 9 months; and maintained with 20mg (oral) every two weeks from Month 9 to 21.” NCT03982771 ↗ “Dexamethasone was also approved as an alternative pharmacological agent for the prevention and treatment of mild and moderate shivering.” NCT06091657 ↗ “dexamethasone administered at a dose of 40 mg (or 20 mg for patients\>75 years old) on Days 1, 8, 15, and 22 of a repeated 28-day cycle.” NCT04674514 ↗ “Given that low dose dexamethasone dramatically improved the response rate of pomalidomide, this drug will be added to the combination.” NCT01889420 ↗ “P.o. cyclophosphamide 300 mg/sqm on days 1, 8 and 15 and p.o. dexamethasone 20 mg on days 1, 2, 8, 9, 15 and 16 in each 28-days series” NCT02572492 ↗ “Intravenous Dexamethasone, 8mg three times per day tapering down for 7 days Per os dexamethasone, 2mg per day tapering down for 7 days” NCT01231009 ↗ “With Intravenous Antiemetic Drugs Dexamethasone and Ondansetron and Incidence of Post-operative Nausea Vomiting for Inner Ear Surgery” NCT02724033 ↗ “CT: Oral 2-4 mg of dexamethasone twice daily for 5 days and then 2-4 mg daily for 5 days at the discretion of the treating physician” NCT05789589 ↗ “HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies” NCT07175415 ↗ “Interscalene brachial plexus blockade using plain bupivacaine with adjuvants: clonidine, epinephrine, buprenorphine, dexamethasone.” NCT03845894 ↗ “Corticosteroid in the form of dexamethasone administered as an oral (liquid or tablets) or intravenous preparation 6 mg once daily” NCT04381936 ↗ “Corticosteroid: 0.5 cc saline and 0.5cc of 10 mg/mL dexamethasone per facet joint (up to 6 mL total volume for 4 facet injections)” NCT04392999 ↗ “Dexamethasone: Patients received intravenous dexamethasone 20 mg daily from days 1 to 5, reduced to 10 mg daily from days 6 to 10.” NCT05658692 ↗ “The liposome formulation of dexamethasone sodium phosphate (TLC599) was developed for the sustained relief of osteoarthritis pain.” PMID 35189943 ↗ Feb 2022 “Group II received injections of 4 mL of 2% preservative-free prilocaine combined with 2 mL or 8 mg of dexamethasone, totaling 6 mL” NCT06507995 ↗ “administration of 20 ml volume of local anesthetics (Lidocaine 2% +Bupivicaine 0.5% 1:1 mixture + 8mg dexamethasone) on each side” NCT06155097 ↗ “dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy aprepitant 80 mg orally D2-4, dexamethasone 8 mg/day orally D2-4” NCT03876938 ↗ “Standard of care therapy can include remdesivir and/or dexamethasone per institutional treatment guidelines or written policies” NCT04351152 ↗ “High-dose dexamethasone (HD-DXM) will be administered orally (40 mg) from day 1-4, followed by Arm 1 or 2 (1:1 randomization).” NCT04812483 ↗ “GDP, gemcitabine 1000 mg/m2 on days 1 and 8, cisplatin 25 mg/m2 on days 1-3, and dexamethasone 40 mg on days 1-4 every 21 days” PMID 32349779 ↗ Apr 2020 “Maximum tolerated dose of Temsirolimus Rituximab (375 mg/m²) Dexamethasone (120 mg) Cisplatin (100mg/m²) Cytarabine (2x2g/m²))” NCT01653067 ↗ “Combination of anti acne cream that contain active substances such as Clindamycin 3%, Dexamethasone 0.05% and Tretinoin 0.05%” NCT04118296 ↗ “All patients will receive pre-surgical ocular surface treatment with intracanalicular sustained release dexamethasone, 0.4 mg” NCT04530864 ↗ “New trio combination is a drug containing 0.1% isobutylamido-thiazolyl-resorcinol, 0.1% retinoic acid and 0.1% dexamethasone” NCT07676994 ↗ “The induction therapy is a combination of Blinatumomab(Blina), Vindesine(VDS), Cyclophosphamide(CTX) and Dexamethasone(DXM).” NCT06742515 ↗ “The study intervention involves implementing a treatment bundle that includes inhaled ipratropium bromide and dexamethasone.” NCT06074185 ↗ “(dexamethasone ophthalmic insert)-for the treatment of ocular inflammation and pain following following ophthalmic surgery.” NCT05372315 ↗ “Group A: Patients who will receive transversus abdominis plane block with - 18ml Bupivacaine 0.25%+ 2 ml Dexamethasone 8mg.” NCT07590752 ↗ “block procedure will involve the use of a local anesthetic solution (10-20 ml of 0.25% bupivacaine and 2 mg dexamethasone)” NCT06298370 ↗ “About 20 patients received Ultrasound-guided (USG-TAP) block with 40 ml of 0.375% levobupivacaine plus 8ml dexamethasone.” NCT06970548 ↗ “The patient in Group I will be given caudal epidural injection with 0.25% ropivacaine 20 ml containing dexamethasone 8 mg” NCT05904275 ↗ “Dexamethasone 5 mg/m2 Days 1 and 2; 10mg/m2 Day 3 to 5; Cyclophosphamide 200 mg/m2 Days 1 and 2 Intrathecal therapy Day 1” NCT04881838 ↗ “* Dexamethasone : D1\~D4 daily oral administration or intravenous injection, 40mg(or 20mg for age for age ≥ 65 years old)” NCT04298372 ↗ “Dexamethasone was injected into the two side of thyroid, the dose of dexamethasone was 5 mg by every side, twice a week.” NCT00917241 ↗ “Medications used during the procedure include 0.75% bupivacaine with or without 1 mg of preservative free dexamethasone.” NCT06621329 ↗ “Comparator Ozurdex® (dexamethasone) was formulated as a rod shaped implant to be inserted into the eye by an applicator.” NCT01396057 ↗ “Parasternal block with Bupivacaine 0.25% + Epinephrine 1:200,000 x 60cc + Dexamethasone 5mg and Dexmedetomidine 50mcg” NCT05191745 ↗ “liposomal Bortezomib-Dexamethasone-Doxorubicin (PAD) alternating with Bortezomib-Dexamethasone-Cyclophosphamide (VCD)” NCT02858999 ↗ “Bendamustine 70-90mg/m2, d1, d2 Liposome Adriamycin 15-20mg/m2, d1 or Adriamycin 10mg d1-d4 Dexamethasone 40mg qw po.” NCT05006469 ↗ “Dexamethasone orally at 20 mg on day of daratumumab administration (pre-daratumumab) and 20 mg on the following day.” NCT03215524 ↗ “Dexamethasone 10mg+ bortezomib (1.3mg /m2 IV) was administered at D1,D4,D8,D11, one month for 1 cycle, for 2 cycles.” NCT05383547 ↗ “Dexamethasone Tablets (administered on Day 1, 12 mg, once daily; administered from Day 2 to 4, 3.75 mg, twice daily)” NCT07124195 ↗ “corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.” NCT06729593 ↗ “corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.” NCT06729606 ↗ “corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.” NCT04843761 ↗ “pulse dose of oral dexamethasone 2.5mg for adults for two consecutive days per week and half the dose for children” NCT06768840 ↗ “The eye will have a sustained release device of Dexamethasone 0.4 mg placed in the inferior nasal lacrimal system.” NCT04563559 ↗ “prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for 12 cycles (28 days/cycle).” NCT00600535 ↗ “powder included dexamethasone, diphenhydramine, tetracycline, metronidazole, nystatin, zinc oxide, and karaya gum” NCT02142543 ↗ “Patients will use the preservative-free dexamethasone 0.1% 4 times a day in the first week after cataract surgery” NCT04050644 ↗ “regimen B is a combination therapy regimen : anlotinib combined with pomalidomide or dalattoumab + dexamethasone.” NCT05549973 ↗ “Dexamethasone, a high-potency, long-acting glucocorticoid, has been shown to prolong peripheral nerve blockade .” NCT04838379 ↗ “If the weekly dose of dexamethasone is 40mg, it should be taken in the first two days of the week, 20mg per day;” NCT05802992 ↗ “treatment with either prednisone or dexamethasone as palliative therapy for the control of neurological symptoms” NCT04461418 ↗ “1 weeks' treatment with nasal tramazoline and dexamethasone compared with 1 weeks' treatment with nasal placebo.” PMID 23397296 ↗ Feb 2013 “R-GDP:rituximab 375mg/m\^2 Day 1 (or Day 8), gemcitabine 1g/m\^2 on Days 1 and 8, dexamethasone 40mg on Days 1-4” NCT03391466 ↗ “infiltration injection of 0.7 ml of dexamethasone lateral to the involved tooth after anesthesia administration.” NCT06457828 ↗ “After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen will be administered.” NCT03467750 ↗ “Recommendations for the management of COVID-19 pneumonia will be followed, including the use of dexamethasone.” NCT04808882 ↗ “Dexamethasone (10mg/d) (Days1-3) Tropisetron (4mg or 4.48mg or 5mg /d) (Days1-3) Olanzapine (10mg/d) (Days1-4)” NCT03571126 ↗ “Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml” NCT04656821 ↗ “Dexamethasone and/or vincristine and/or pegasparaginase OR cytarabine and/or etoposide and/or pegasparaginase” NCT03236857 ↗ “or a bioequivalent dose of oral corticosteroids (e.g., 1,250mg prednisone daily or 176mg dexamethasone daily)” NCT07100990 ↗ “Randomized to dexamethasone ophthalmic insert 0.4mg placed prior to cataract surgery, on the day of surgery.” NCT05023304 ↗ “Study of Dexamethasone-Allantoin-Metronidazole (DAM) Solution in the Treatment of Post-Operative Ileus (POI)” NCT01863407 ↗ “8 mg dexamethasone was applied into the tibio-femoral joint with a 22-gauge, 10 cm needle under fluoroscopy.” NCT06017674 ↗ “Patients undergo induction therapy with 6 cycles of daratumumab, bortezomib, lenalidomide and dexamethasone” NCT05231629 ↗ “This insert allows for sustained release of dexamethasone onto the ocular surface over a period of 28 days.” NCT06235567 ↗ “CVAD is the acronym of the drugs in course a: cyclophosphamide, vincristine, doxorubicin and dexamethasone.” NCT05581030 ↗ “5-HT3 Receptor Antagonist, NK1 Receptor Antagonist, Dexamethasone administered orally, IV, or transdermally” NCT07169851 ↗ “Patients will receive adjuvant dexmedetomidine (25mcg) and dexamethasone (5mg) in addition to bupivacaine.” NCT06658054 ↗ “Dose group 1 received 114ug of dexamethasone, Dose group 2 received 513ug and Dose group 3 received 684ug.” NCT01048593 ↗ “early use of dexamethasone/Methylprednisolone as early as laboratory evidence of high inflammatory markers” NCT04530409 ↗ “30 mL of 0.25% bupivacaine + 0.5 mL (5 mg) preservative-free dexamethasone + 0.1 mL epinephrine 1:400,000.” NCT05996133 ↗ “Vincristine 0.5 mg/d d 1 - 4 CI Adriamycin 10 mg/m2/d d 1 - 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20” NCT00580372 ↗ “Effect of pre-medication with anti-inflammatory drugs(ibuprofen and dexamethasone)on Post-Endodontic pain” NCT06980870 ↗ “patients in group( SD )will receive 8-mg dexamethasone IV in 500-mL normal saline after spinal anesthesia” NCT04778189 ↗ “Dexamethasone 10mg or Depomedrol 40mg, together with Bupivacaine 0.25% (for 3-5mL total injectate volume)” NCT02103543 ↗ “Patients will receive a single intraoperative dose of 10mg of intravenous dexamethasone intraoperatively.” NCT04738318 ↗ “The injectate in the active arm will contain a combination of bupivacaine, epinephrine and dexamethasone.” NCT04019834 ↗ “Low-dose lenalidomide continuous SC infusion (STAR-LDD) in combination with bortezomib and dexamethasone” NCT06087653 ↗ “FST-100 (PVP-I 0.4% and dexamethasone 0.1%). A regimen of 2 drops 4 times a day while awake for 5 days.” NCT00941486 ↗ “One dose of Dexamethasone (20mg/day) followed by prednisone 1mg/kg/day with a maximum dose of 60mg/day.” NCT00953303 ↗ “Dexamethasone improves the quality and duration of peripheral nerve block over local anaesthetic alone.” NCT04551833 ↗ “Pemetrexed 15 mg was administered with dexamethasone 5 mg via intraventricular or via lumbar puncture.” NCT06296745 ↗ “Intrathecal chemotherapy with 40mg of pemetrexed and 2mg of dexamethasone, every 3 weeks as one cycle.” NCT07304739 ↗ “standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflurane” NCT01868425 ↗ “A 6ml solution of 4ml 0.25% Bupivacaine, 1ml 40mg Kenalog, and 1ml 4mg Dexamethasone will be prepared.” NCT01688362 ↗ “In group A, the investigators used combined Lidocaine 2% and dexamethasone (8mg/2ml) with ratio (1:1).” NCT03265197 ↗ “Paracetamol, Vitamin D, Oxygen if indicated, Low molecular weight heparin, dexamethasone if indicated” NCT04523831 ↗ “prednisolone/prednisone 5 mg taken orally twice daily or dexamethasone 0.5 mg taken orally once daily” NCT01664728 ↗ “Dexamethasone is a potent and highly selective glucocorticoid with minimal mineralocorticoid effect.” NCT04715152 ↗ “During treatment, participants receive dexamethasone 20 mg orally 12 to 6 hours prior to paclitaxel;” NCT01953536 ↗ “Initial Cytoreduction is performed with DHAP- protocol using dexamethasone, cytarabine and cisplatin” NCT00384553 ↗ “Dexamethasone was given 20 mg orally on days 1, 8, 15 and 22, limited to the two first cycles only.” PMID 39909655 ↗ Feb 2025 “Intravenous ceftriaxone with either oral methyl prednisolone or intravenous dexamethasone was given” NCT04935515 ↗ “Bupivacaine, Dexamethasone, Epinephrine for hernia patients receiving abdominal wall reconstruction” NCT07518238 ↗ “dexamethasone ((Dexaven 4mg/ml, Jelfa, Poland) in a dose of 4 mg will be administered intravenously” NCT06609993 ↗ “Intravenous analgesia with ketoprofen, dipyrone and dexamethasone. IV morphine to rescue analgesia” NCT02239497 ↗ “A single DEXTENZA® releases a 0.4 mg dose of dexamethasone for up to 30 days following insertion.” NCT04529512 ↗ “Dexamethasone (4mg ampoule, intravenous) Dose: 6mg intravenous every day for a maximum of 10 days” NCT04536363 ↗ “Experimental: Drug:Fosrolapitant and Palonosetron for injection Drug:Dexamethasone Drug: placebo” NCT07692451 ↗ “An intravenous injection of 8 mg of Dexamethasone is added to prolong the duration of the block.” NCT03984656 ↗ “Corticosteroid agent used is either Dexamethasone 8 mg or Triamcinolone acetonide 0.3-0.6 mg/kg” NCT07713329 ↗ “dexamethasone 8mg, methylprednisolone 80mg and bupivacaine 5ml 0.25%, intra articular injection” NCT07489521 ↗ “A single intravenous 20 mg dose of dexamethasone will be applied one hour before starting dose.” NCT06886074 ↗ “gelatin sponge sheet covered with thrombin and tobramycin and dexamethasone ophthalmic ointment” NCT06175676 ↗ “OFA (n=159) consisting of intravenous ketamine, dexamethasone, lidocaine, and magnesium sulfate” PMID 42190101 ↗ May 2026 “The ALLR3 chemotherapy regimen (vincristine, mitoxantrone, dexamethasone, and PEG-asparaginase” NCT05748171 ↗ “NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) ophthalmic gel” NCT02973880 ↗ “high dose dexamethasone : 40mg/day , D1-D4, D9-D12, IV or PO, repeat every 21days for 2cycles” NCT01255514 ↗ “Patients will receive 20 ml 0.25% bupivacaine plus 4 mg dexamethasone on each side TAB bock.” NCT05323565 ↗ “P (Prednisone): 60 mg/m²/day (max 100 mg/day) or equivalent dexamethasone dose on days 1-14.” NCT06930105 ↗ “Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone (Hyper-CVAD)” NCT01184885 ↗ “All participants receive dexamethasone (given orally at a dose of 40 mg per day for 4 days)” NCT02834468 ↗ “single injection,5ul solution,concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone” NCT06497699 ↗ “Dexamethasone is a corticosteroid that is similar to a natural hormone made by your body.” NCT01440582 ↗ “premedication of Dexamethasone, Paracetamol, Vimovo; postoperative Paracetamol and Vimovo” NCT02604446 ↗ “Dexamethasone sodium phosphate is fluoromethyl prednisolone, a synthetic glucocorticoid.” NCT05999955 ↗ “The Effect of Dexamethasone in Full Pulpotomy on Postoperative Pain in Permanent Molars” NCT07233577 ↗ “intracanalicular dexamethasone (0.4mg) insert compared to standard steroid drop regimen” NCT04281862 ↗ “Dextenza is a 0.4mg dexamethasone ophthalmic insert manufactured by Ocular Therapeutix.” NCT05587231 ↗ “cyclophosphamide 500mg D1-8-15 + thalidomide 100-200mg D1-28 + dexamethasone 40mg/week” NCT03792620 ↗ “bortezomib along with dexamethasone and pegylated liposomal doxorubicin (Doxil/Caelyx)” NCT00570180 ↗ “Initiation : cyclosporine 3mg/kg p.o.bid + dexamethasone 10mg/m2/d po. or i.v. (D1-3)” NCT01547143 ↗ “dexamethasone 8mg intramuscular every 12hours for 48 hours i.e. in four divided doses” NCT03473210 ↗ “group D will receive Inj Bupivicain plus Dexamethasone in Erector Spinae Plane Block.” NCT05277974 ↗ “Fludarabine 40mg/m2 po.d1-3; Adriamycin 50mg/m2 i.v.d1; Dexamethasone 20mg/d po.d1-5.” NCT00840385 ↗ “Drug: Dexamethasone, Dexamethasone (20mg, iv, on days 1-4, 8-11of each 28 day cycle)” NCT01852799 ↗ “Brentuximab Vedotin Etoposide Cyclophosphamide Doxorubicin Dacarbacine Dexamethasone” NCT06919679 ↗ “Group B : will receive bupivacaine 0.25% +dexamethasone (8 mg), total volume(20 ml)” NCT06294665 ↗ “oral dexamethasone 7.5mg pretreatment 12h, 3h, 1h before each infusion of docetaxel” NCT06306612 ↗ “Dexamethasone 4 mg evening before, morning of and evening of each dose of docetaxel” NCT00541099 ↗ “Dexamethasone 8mg orally twice a day for 6 doses (starting on the morning of day 2)” NCT04075955 ↗ “Dexamethasone 0.013 mg/kg fat-free mass daily taken orally for a total of 21 days.” NCT00805207 ↗ “Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g applied 2 times / day at lesion” NCT01257061 ↗ “Ropivacaine 0.5% total dose 3mg/kg with Dexamethasone 8mg/20 ml Ropivacaine 0.5%.” NCT04338984 ↗ “2 to 4 cycles of IV P-DHAP (pembrolizumab, dexamethasone, cytarabine, cisplatin)” NCT04838652 ↗ “Take orally (cetirizine 10 mg bid, dexamethasone 8 mg bid, ranitidine 150 mg bid” NCT05922358 ↗ “Daratumumab in combination with Gemcitabine, Dexamethasone and Cisplatin (D-GDP)” NCT04251065 ↗ “5ul dexamethasone, concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone” NCT06429306 ↗ “Dexamethasone 20(20-40) mg PO/IV daily for 5 consecutive days, every 14 - 28 day” NCT00117598 ↗ “Id: Ixazomib 4mg po d1,8,15; Dexamethasone 20mg po d1,8,15,22; (28 days /cycle).” NCT05477797 ↗ “DexaEDO (dexamethasone) eyedrops without preservatives are applied additionally.” NCT01228149 ↗ “following the use of intravitreal dexamethasone implant for the treatment of DME” NCT04038125 ↗ “Dexamethasone 10 mg/m2/day IV 1 - 5 days, Methotrexate 1000 mg/m2 12 h IV 1 day” NCT02842931 ↗ “Cyclophosphamide + Doxorubicin + Vincristine + Dexamethasone (DXM)] ± Rituximab” NCT06520163 ↗ “Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4” NCT02130817 ↗ “salvage chemotherapy with intravenous dexamethasone/cisplatin/cytarabine (DHAP)” NCT00003143 ↗ “Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present” NCT04475991 ↗ “tobramycin/dexamethasone (TobraDex ST ; 'ST') ophthalmic suspension 0.3%/0.05%” PMID 21138337 ↗ Dec 2010 “2ml(4mg/ml) of dexamethasone administered two hours prior to Mw administration” NCT01424735 ↗ “Eltrombopag Oral Tablet 25-75 mg daily for 12 weeks plus pulsed dexamethasone” NCT03830749 ↗ “magic mouthwash (diphenhydramine, dexamethasone and nystatin) plus sucralfate” NCT00814359 ↗ “Patients received a single intravitreal injection with 340 µg dexamethasone.” PMID 36542081 ↗ Oct 2022 “Bupivacaine 0.25% + Lidocaine 1% + dexamethasone 4 mg + epinephrine 5 mcg/ml” NCT05834023 ↗ “All patients received 8 mg dexamethasone and lidocaine at a dose of 1 mg/kg.” NCT06958913 ↗ “fixed-dose MAD (Methotrexate, L-asparaginase and Dexamethasone) chemotherapy” NCT03246750 ↗ “Dexamethasone + Neomycin Sulfate + Polymyxin B Sulfate - Lab. Union Chemical” NCT01227863 ↗ “Oral or parenteral corticosteroid (e.g., dexamethasone, methylprednisolone)” NCT05819541 ↗ “treatment with 700 microg or 350 microg of dexamethasone DDS or observation” PMID 20212197 ↗ Mar 2010 “methotrexate (15 mg/m 2 ), cytarabine (40 mg/m 2 ) and dexamethasone (4 mg)” NCT02396043 ↗ “Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide” NCT01160484 ↗ “Dexamethasone 40mg PO or IV at D1-4 (dose diminution at 20 mg for Age ≥65y)” NCT03599960 ↗ “DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use” NCT05620901 ↗ “with or without intratympanic dexamethasone 5 mg/ml injection for 2-4 times” NCT06467526 ↗ “one month of topical G. Dexamethasone 0.1% with Neomycin sulphate 3500IU/g” NCT00789971 ↗ “Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily” NCT00781768 ↗ “treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone.” NCT06771180 ↗ “Dexamethasone 40 mg/p.o. days 1-4 and 9-12 cycles 1-4 (Cycles of 21 days)” NCT01084837 ↗ “Premedication/Precautions: Dexamethasone 4mg IV, Diphenhydramine 25 mg IV” NCT05768919 ↗ “Ropivacaine and Adrenalin, systemic Ketorolac and high dose Dexamethasone” NCT02374008 ↗ “* Dexamethasone 200 mg Intravenous Infusion "Piggy-Back" (IVPB) Days 1-7” NCT00577512 ↗ “combination with dexamethasone given orally as a 20 mg daily for 4 days” NCT00229203 ↗ “200 mL Ringer solution+1mg dexamethasone after finishing the irrigation” NCT01958879 ↗ “dexamethasone 8mg for anti-inflammatory and antiemetic before operation” NCT05577962 ↗ “the patients will be given 4mg dexamethasone and or 4mg ondansetron IV.” NCT02288923 ↗ “Single preoperative 0.1 mg/kg dose dexamethasone has a combined action” NCT04238377 ↗ “Dexamethasone given orally only on days 1, 8, 15, and 22 of each cycle” NCT06158412 ↗ “Dextenza (dexamethasone) 0.4mg intracanalicular insert delivery system” NCT04687800 ↗ “glucocorticosteroid (prednisone, dexamethasone or methylprednisolone)” NCT02188368 ↗ “Dexamethasone 20 mg/m2 P.O. or I.V. (divided BID) - D1-D5 and D15-D19” NCT06034561 ↗ “SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension” NCT03004924 ↗ “Ciprodex (0.3% Ciprofloxacin and Dexamethasone 0.1% Otic Suspension)” NCT01359098 ↗ “Dexamethasone: 0.3mg/kg per dose for 3 days (minimum weight 20 kgs )” NCT01326494 ↗ “Dexamethasone: 20 mg/d, orally on days 1, 2, 4, 5, 8, 9, 11, and 12.” NCT06246162 ↗ “Epidural analgesia with lidocaine 2%, 1.5 ml, and Dexamethasone 8 mg” NCT04108546 ↗ “Dexamethasone will be given as pills to be taken for 4 days in a row” NCT00836173 ↗ “0.1% dexamethasone and 0.6% polyvinylpyrrolidone iodine (PVP-Iodine)” NCT01470664 ↗ “hCRF ; open-label dexamethasone that the patient is currently taking” NCT00088166 ↗ “One arm will receive one capsule of 6 mg of dexamethasone for 7 days” PMID 41005772 ↗ Sep 2025 “Dexamethasone 3mg/m2/dose (max 8 mg/dose) PO BID on Days 7, 8, and 9” NCT05634369 ↗ “Ocular Therapeutix Dextenza (Dexamethasone Ophthalmic Insert) 0.4 mg” NCT04549935 ↗ “preservative-free dexamethasone (DEX), diclofenac (DICLO) eye drops” PMID 36602718 ↗ Jan 2023 “103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg” NCT05550350 ↗ “103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg” NCT05550363 ↗ “Dexamethasone (8 mg, orally, 12/3/1 hour before docetaxel infusion)” NCT07172685 ↗ “HAIP will be filled with mixture of Floxuridine and Dexamethasone.” NCT03366155 ↗ “Dexamethasone (D): 10 mg/m2 IV over 15 minutes on Day 1 and Day 2” NCT01858922 ↗ “2 ml of dexamethasone will be administered in an 8 mg/2 ml ampoule” NCT06788158 ↗ “local injection at surgical site of 40 mg\\ dose of dexamethasone” NCT06307106 ↗ “Dexamethasone is a potent synthetic member of the corticosteroid.” NCT01277731 ↗ “Preservative free dexamethasone 0.1% (Monopex) drops for one week” NCT05433428 ↗ “Dexamethasone: 20mg/day oral route on days 1, 8, 15, 22 per cycle” NCT02244125 ↗ “intravenous ondansetron 8 mg, and intravenous dexamethasone 12 mg” NCT06007586 ↗ “dexamethasone only or in combination with any other glucorticoid” NCT02716818 ↗ “PIFB with bupivacaine, epinephrine, clonidine, and dexamethasone” NCT05676814 ↗ “Patients will receive dexamethasone (8 mg i.v.) after induction.” NCT05481970 ↗ “patients given intraoperative dexamethasone after hernia removal” NCT07411326 ↗ “dexamethasone p.o. (by mouth) (days 1, 2, 4, 5, 8, 9, 11 and 12)” NCT00872521 ↗ “Dexamethasone 12 mg on Day 1 and 8 mg daily from Day 2 to Day 4” NCT03831633 ↗ “IRd chemotherapy with ixazomib, lenalidomide, and dexamethasone” NCT04405167 ↗ “PO Dexamethasone (included with benzocaine in local anesthesia)” NCT03738904 ↗ “Intracanalicular sustained release dexamethasone insert 0.4 mg” NCT04464629 ↗ “Dexamethasone eye drop, 1 drop, qid, for 3 days before surgery” NCT01824927 ↗ “Maxidex (0.1% Dexamethasone) 1 drop in each eye 2 times daily” NCT00631358 ↗ “Corticosteroids (methylprednisolone/dexamethasone/prednisone)” NCT04380818 ↗ “Cyclophosphamide 300 mg x1; dexamethasone x 7; vincristine x1” NCT05253495 ↗ “Corticosteroids (Dexamethasone), Anticoagulants (LMW heparin)” NCT05413642 ↗ “Duloxetine and Dexamethasone for Improving Postoperative Pain” NCT03250494 ↗ “Dexamethasone: 20 mg IV or PO Days 1, 2, 8, 9, 15, 16, 22, 23” NCT07601100 ↗ “Dexamethasone (DEX): 10 mg/m2 bolus days 1 and 2 IV, 8 to 11” NCT01366898 ↗ “R-DHAP (Rituximab , Dexamethasone, Ara-C, Cisplatine, G-CSF)” NCT02858258 ↗ “oral dexamethasone (20 mg po at day-1, day-4, day-8, day-11)” NCT02201576 ↗ “Solanum Night Cream (Clindamisin + Retinoid + Dexamethasone)” NCT07504822 ↗ “dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle” NCT00823719 ↗ “Tapering dose of dexamethasone or prednisolone upto 8 weeks” NCT05917340 ↗ “dexamethasone 20 mg on days 1-4, administered intravenously” NCT03392714 ↗ “Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT” NCT01679860 ↗ “Dexamethasone: administrated once weekly every 28day cycles” NCT03150316 ↗ “Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day” NCT01631916 ↗ “dexamethasone (D, 20 mg) is given intravenously on days 1-4” NCT07604987 ↗ “OTX-DED (dexamethasone intracanalicular ophthalmic insert)” NCT05814757 ↗ “OTX-DED (dexamethasone intracanalicular ophthalmic insert)” NCT04747977 ↗ “Dexamethasone (D) (maximum period of treatment= 24 cycles)” NCT03891355 ↗ “dexamethasone (40 mg orally on days 1, 8, 15, and 22; KCd)” PMID 36529145 ↗ Dec 2022 “the use of 3-day dexamethasone (DEX) is often recommended” PMID 32735029 ↗ Aug 2020 “Drug:dexamethasone 40mg/d,d1-4,d11-14, IV, in cycle 2,4,6” NCT02042690 ↗ “dexamethasone 8 mg (2 ml) mixed with the local anesthetic” NCT00519584 ↗ “dexamethasone (20mg/d orally on days 1-4 and days 11-14)” NCT02404571 ↗ “dexamethasone: 40mg (20mg for ≥75yr) on day 1, 8, 15, 22” NCT07348393 ↗ “GDP (gemcitabine, cisplatin, dexamethasone) chemotherapy” NCT02276248 ↗ “Intracanalicular Dexamethasone ophthalmic insert (0.4mg)” NCT05116345 ↗ “Blinatumomab, Dasatinib, Methotrexate, and Dexamethasone” NCT06773936 ↗ “dexamethasone 15mg/m2 intravenously on days 1 through 5” NCT06255795 ↗ “Cyclophosphamide,Liposome doxorubicin and Dexamethasone” NCT02336386 ↗ “Change of prednisone 5mg/12h to dexamethasone 0.5mg/24h” NCT02928432 ↗ “5 ml of normal saline containing 8 mg of dexamethasone” NCT06166108 ↗ “-4mg dexamethasone, 1mg haloperidol, scopolamine patch” NCT04081545 ↗ “tobramycin 0.3% + dexamethasone 1% - União Química Lab” NCT01227915 ↗ “Single intratympanic injection of 12 mg dexamethasone” NCT03664674 ↗ “Part A: cyclophosphamide, vincristine, dexamethasone” NCT07294677 ↗ “Solumedrol, dexamethasone,prednisolone, azithromycin” NCT04871633 ↗ “4. dexamethasone 20mg on day 1-4, intravenous drip.” NCT06314334 ↗ “Dexamethasone 4mg and Ondansetron 4mg intravenously” NCT01511627 ↗ “Betamethasone, dexamethasone, or methylprednisolone” NCT05401812 ↗ “oral dexamethasone (40 mg on days 1, 8, 15, and 22)” NCT04991103 ↗ “Cycles 5-8: every month Dexamethasone: 40 mg weekly” NCT04288765 ↗ “Magnesium sulphate 2.5-5g and Dexamethasone 8-16mg” NCT05172739 ↗ “rituximab + dexamethasone + cytarabine + cisplatin” NCT02055924 ↗ “dexamethasone 40 mg PO or IV day1\~4 every 3 weeks” NCT02445404 ↗ “15cc 0.25% of Bupivacaine + Dexamethasone 8 mg 2cc” NCT07049835 ↗ “Pre-op dexamethasone 4mg IV and midazolam 1-2mg IV” NCT03448068 ↗ “Magnesium sulphate 2.5-5g and Dexamethasone 8-16mg” NCT04894864 ↗ “12 mg dexamethasone administered intratympanically” NCT02997189 ↗ “Dexamethasone will be given by mouth on Days 1-4.” NCT05852717 ↗ “Dexamethasone 9 mg/m²/day, intravenous, days 1-7.” NCT07564453 ↗ “One (1) IBE-814 IVT Implant (70 μg Dexamethasone)” NCT04576689 ↗ “Dextenza (Dexamethasone Ophthalmic Insert 0.4 mg)” NCT04563299 ↗ “single dose of dexamethasone (8mg) will injected” NCT01896427 ↗ “Bortezomib and Dexamethasone according to label.” NCT03136653 ↗ “Dexamethasone 40 mg/m 2 days 1-4, 9-12 and 17-20” NCT00560053 ↗ “SMO1 (Dexamethasone 700μg intravitreal implant)” NCT07708142 ↗ “Humanized mAb targeting CD47 plus dexamethasone” NCT04445701 ↗ “Premedication includes 20 mg of dexamethasone.” NCT06977594 ↗ “Drug: Dexamethasone(40mg, orally, on days 1-4)” NCT01868828 ↗ “intracanalicular dexamethasone (0.4mg) insert” NCT04839549 ↗ “Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22” NCT01701076 ↗ “sustained release dexamethasone 0.4 mg insert” NCT04592081 ↗ “Oral dexamethasone + Standard premedications” NCT07469488 ↗ “* Dexamethasone 4-8 mg for PONV prophylaxis,” NCT07337135 ↗ “Dexamethasone will be mixed with bupivacaine” NCT01756573 ↗ “magnesium, dexamethasone and dexmedetomidine” NCT04747171 ↗ “DPACE: dexamethasone 20 mg days 1-4 and 8-11” NCT00670631 ↗ “with dexamethasone 12 mg administered orally” NCT03386617 ↗ “1. dexamethasone :40mg/day D1-4, intravenous” NCT04065308 ↗ “PO or IV dexamethasone 40mg D1, 8, 15 and 22” NCT03143049 ↗ “Dexamethasone 20 mg PO days 1, 4, 8, and 11” NCT00581919 ↗ “Dexamethasone 40mg/d po or iv on D1-4, 8-11” NCT01370434 ↗ “MVD: Methotrexate,Vincristine,Dexamethasone” NCT01083342 ↗ “5mg (0.5mL) preservative free dexamethasone” NCT05224089 ↗ “dexamethasone 10mg intravenously on days1-3” NCT07000617 ↗ “Pre \& Post medication Dexamethasone 8mg PO” NCT00313872 ↗ “ISV-305 (0.1% Dexamethasone in DuraSite® 2)” NCT03192150 ↗ “ISV-305 (0.1% Dexamethasone in DuraSite® 2)” NCT03192137 ↗ “Dexamethasone: 40 mg/day (PO/IV, Days 1-4).” NCT07059156 ↗ “Dexamethasone 40 mg day 1-4 of every cycles” NCT02374424 ↗ “Bortezomib, Lenalidomide and Dexamethasone” NCT05860036 ↗ “Bortezomib, Lenalidomide and Dexamethasone” NCT05850286 ↗ “Dexamethasone and antiemetic premedication” NCT00216138 ↗ “dexamethasone 40 mg on Days 1, 2, 3, and 4” NCT01453205 ↗ “Bortezomib, Lenalidomide and Dexamethasone” NCT05979363 ↗ “D, Dexamethasone oral: 40mg (days 1 to 4)” NCT04348006 ↗ “dexamethasone at doses of 4 - 20 mg / day” NCT05187793 ↗ “Dexamethasone: 20-40mg, po, d1,d8,d15,d22” NCT03908138 ↗ “Dexamethasone, 4 mg I.V. (Intraoperative)” NCT04110587 ↗ “biodegradable 0.7mg dexamethasone implant” NCT01701518 ↗ “Dexamethasone 10 mg/m2/day IV 1 - 5 days” NCT03479918 ↗ “Dexamethasone, 40mg/d IV, day 1 to day 4” NCT02733458 ↗ “Dexamethasone, 40mg/d iv, day 1 to day 4” NCT02764281 ↗ “Dexamethasone 40 mg/day IV or PO on D1-4” NCT05966233 ↗ “dexamethasone 40 mg p.o. or i.v. d 15-19” NCT00517894 ↗ “Dexamethasone : 40 mg/j, days 1, 8 et 14” NCT01206205 ↗ “equivalent dose of dexamethasone at 15mg” NCT06486337 ↗ “dexamethasone 12 mg po D1, 8 mg po D2-4” NCT01536691 ↗ “OZURDEX® Implant 700 µg (Dexamethasone)” NCT03908307 ↗ “sustained released dexamethasone, 0.4mg” NCT04863742 ↗ “a moderate amount of dexamethasone i/v” NCT04461925 ↗ “Ketamine 0.5 mg/kg; Dexamethasone 8 mg” NCT07414706 ↗ “dexamethasone 6 mg PO every other day” NCT01302392 ↗ “Lenalidomide (Revlimid)/Dexamethasone” NCT01711671 ↗ “dexamethasone(6mg, oral, day 1-day 5)” NCT04536558 ↗ “dexamethasone 20mg/ m2,VD d2,d3,d4,d5” NCT01933282 ↗ “Intracameral Dexamethasone (Dexycu™)” NCT04781335 ↗ “dexamethasone 20mg/m2 iv on days 3-6” NCT02560441 ↗ “Adjunction of dexamethasone (HD DXM)” NCT00777738 ↗ “Dexamethasone, Cytarabine, Cisplatin” NCT01453504 ↗ “Dexamethasone: low dose for 10 days” NCT07711964 ↗ “Dexamethasone 5 mg/m2/dose on Day 1” NCT05827549 ↗ “dexamethasone (total dose 30 mg/m2)” NCT04499573 ↗ “Dexamethasone intravitreal implant” NCT04856397 ↗ “DXM(dexamethasone),40mg/d,p.o,d1-4” NCT02520219 ↗ “Dexamethasone 40 mg/d i.v. (d1-3)” NCT02531841 ↗ “Dexamethasone 40mg D1-4 oral/I.V.” NCT06255704 ↗ “Dexamethasone 40mg D1-4 oral/I.V.” NCT04736914 ↗ “Dexamethasone: Orally once weekly” NCT05651932 ↗ “dexamethasone(DXM) 10 mg days 1-8” NCT02520479 ↗ “dexamethasone 8 mg will be added.” NCT05624957 ↗ “Dexamethasone 10mg should be used” NCT05561699 ↗ “dexamethasone 40 mg IVD on day 2” NCT01457144 ↗ “or sub-Tenon dexamethasone depot” PMID 34383010 ↗ Oct 2021 “Corticosteroids (Dexamethasone)” NCT05249790 ↗ “Dexamethasone, 40mg, p.o. d2-d4” NCT06069830 ↗ “Dexamethasone 20mg iv.drip d1-4” NCT04624958 ↗ “dexamethasone 10mg ivgtt d2-6.” NCT05809180 ↗ “dexamethasone 20 mg days 1 - 4” NCT03154918 ↗ “dexamethasone 40 mg on Day 1-4” NCT01626664 ↗ “Dexamethasone 40 mg PO weekly.” NCT03601624 ↗ “12 mg OTO-104 (dexamethasone)” NCT02265393 ↗ “Dexamethasone 6mg Po QD, D1-7” NCT05244577 ↗ “dexamethasone 40mg,po/iv d1-4” NCT06062641 ↗ “5mg / week oral dexamethasone” NCT05706636 ↗ “Day 1: Dexamethasone 20 mg PO” NCT05099471 ↗ “B :dexamethasone (DECTANCYL)” NCT02552251 ↗ “ISV-305 (0.1% Dexamethasone)” NCT01543490 ↗ “Dexamethasone 10mg,ivg, d1-4” NCT03105596 ↗ “* Dexamethasone * Rituximab” NCT00801580 ↗ “Dexamethasone 40 mg day 1-4” NCT01805557 ↗ “dexamethasone 40mg, iv D1-4” NCT03373019 ↗ “Dexamethasone 40 mg PO 1-4” NCT00113919 ↗ “Dexamethasone (DECADRON®)” NCT00538733 ↗ “Dexamethasone (Decadron®)” NCT02128230 ↗ “Dexamethasone 40mg, d1-4” NCT04134247 ↗ “dexamethasone 40mg D1-4” NCT05244642 ↗ “Dexamethasone: 4-8mg IV” NCT07558226 ↗ “Dexamethasone (DXM ) :” NCT02036489 ↗ “dexamethasone 4 mg tid” NCT07584525 ↗ “dexamethasone (oral)” NCT03181126 ↗ “Drug: Dexamethasone” NCT03763370 ↗ “Drug: Dexamethasone” NCT00247416 ↗ “Drug: Dexamethasone” NCT03206671 ↗ “Drug: Dexamethasone” NCT07442890 ↗ “Dexamethasone 0.4mg” NCT05626478 ↗ “DEXAMETHASONE 8 mg” NCT02884440 ↗ “dexamethasone 8mg” NCT03518463 ↗ “8mg Dexamethasone” NCT07568938 ↗ “dexamethasone” NCT05246631 ↗ “Dexamethasone” NCT04348006 ↗ “Dexamethasone” NCT06172257 ↗ “Dexamethasone” NCT01672736 ↗ “Dexamethasone” NCT03837873 ↗ “Dexamethasone” NCT00734877 ↗ “Dexamethasone” NCT01575925 ↗ “dexamethasone” NCT01606735 ↗ “Dexamethasone” NCT03335098 ↗ “dexamethasone” NCT02872597 ↗ |
| Known as | AR-1105 | “PURPOSE: AR-1105 is a novel biodegradable sustained-release dexamethasone implant designed to deliver 6-month durability.” PMID 36542081 ↗ Oct 2022 |
| Known as | AR-1105-CF1 (dexamethasone intravitreal implant) | “AR-1105-CF1 (dexamethasone intravitreal implant)” NCT03739593 ↗ |
| Known as | AR-1105-CF2 (dexamethasone intravitreal implant) | “AR-1105-CF2 (dexamethasone intravitreal implant)” NCT03739593 ↗ |
| Known as | Corodex | “The patients will receive Dexamethasone 8 mg (Corodex, Laboratorio Celsius, Montevideo, Uruguay) PO 1 hour before surgery (Almeida et al 2019)” NCT05924191 ↗ |
| Known as | Decadron | “Anesthesia will be maintained with Sevoflurane, Magnesium, Lidocaine, Ketamine, Decadron, Ondansetron, and Ketorolac at a concentration range/dose(s) based on the clinical need...” NCT03367988 ↗29“Dexamethasone (Decadron®) will be given orally at a dose of 40 mg on days 1, 2, 3, 8, 15 and 22 during the first cycle and once a week on days 1, 8, 15, and 22 for each...” NCT00151203 ↗ “Dexamethasone (Decadron) caused minimal damage, while hydrocortisone (Solu-Cortef) and triamcinolone hexacetonide (Aristospan) caused widespread axonal and myelin degeneration.” PMID 7063571 ↗ Mar 1982 “QL block involves injection of 19 ml of 0.25% Bupivacaine and iml(4mg) of Decadron in a fascial place formed partly by the posterior surface of the quadratus lumborum muscle” NCT05480111 ↗ “The purpose of this study is to compare the safety and efficacy of XERECEPT® to dexamethasone (Decadron) a common treatment for symptoms of brain swelling (edema).” NCT00088166 ↗ “The medication used for the block are clonidine 100 mcg, Decadron PF 5mg and 0.25% bupivacaine 5 mL. This medication will be administered once during the block.” NCT04445337 ↗ “A Phase II Study of Dexamethasone (DECADRON®), Thalidomide (THALOMID®), and Lenalidomide (REVLIMID®) for Subjects With Relapsed or Refractory Multiple Myeloma” NCT00538824 ↗ “The names of the study drugs involved in this study are: * Teclistamab * Lenalidomide (also called Revlimid) * Dexamethasone (also called Decadron)” NCT05469893 ↗ “Steroids (such as Decadron or Dexamethasone) are medication used to reduce swelling around the tumour, and thus symptoms improve.” NCT00188864 ↗ “dexamethasone sodium phosphate (Decadron; 4 mg/mL; soluble). Again, this will be mixed with 1% lidocaine without epinephrine” NCT03641508 ↗ “Decadron will be given at a dose of 0.2 mg/kg intraoperatively, followed by Decadron 4 mg. every 6 hours for 24 hours.” NCT01065961 ↗ “.075 mg IV Palonosetron (Aloxi) with 8mg IV Dexamethasone (Decadron) before surgery to see if this reduces PONV.” NCT00952133 ↗ “This was placed under ultrasound using 30 ml of 0.25% bupivacaine and 4 mg of Decadron.” NCT05257941 ↗ “dexamethasone (Decadron) 8 mg oral daily on days 2-4.” NCT05590923 ↗ “(volume per MD based on pt weight) + decadron” NCT04180943 ↗ “Dexamethasone (Decadron) 8mg IM injection” NCT07109258 ↗ “Dexamethasone (DECADRON®)” NCT00538733 ↗ “Dexamethasone (Decadron)” NCT02793843 ↗ |
| Known as | Decadron (dexamethasone) | “Decadron (dexamethasone)” NCT00783367 ↗ |
| Known as | Decadron for Dexamethasone | “Decadron for Dexamethasone” NCT01270932 ↗ |
| Known as | Decadron PF | “The medication used for the block are clonidine 100 mcg, Decadron PF 5mg and 0.25% bupivacaine 5 mL. This medication will be administered once during the block.” NCT04445337 ↗ |
| Known as | Decort | “The pulp chamber was irrigated with 2 mL of a dexamethasone sodium phosphate solution at a concentration of 4 mg/mL (Decort®, DEVA Holding, Türkiye).” NCT07233577 ↗ |
| Known as | DECTANCYL | “B :dexamethasone (DECTANCYL)” NCT02552251 ↗ |
| Known as | Desamethasone | “* Desamethasone 40 mg days 1-4” NCT02371161 ↗ |
| Known as | DEX | “The non-inferiority of dexamethasone (DEX) on day 1, with or without low-dose DEX on days 2 and 3, combined with oral NEPA (netupitant/palonosetron), compared with the...” PMID 35999527 ↗ Aug 202246“This study will investigate the efficacy and safety of OZURDEX® (dexamethasone intravitreal implants; DEX, Allergan, Inc. Irvine, CA) as monotherapy for the treatment of...” NCT05101928 ↗ “The aim of this study is to evaluate the effectiveness of submucosal 8 mg (2 mL) dexamethasone (DEX) on postoperative pain, swelling, chewing efficiency, trismus, healing, and...” PMID 39627624 ↗ Dec 2024 “D (Dexamethasone) group: (n=100) each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS...” NCT03679065 ↗ “PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR...” NCT00002716 ↗ “OBJECTIVE: To compare the efficacy of a single dose of oral dexamethasone (Dex) versus 5 days of twice-daily prednisolone (Pred) in the management of mild to moderate asthma...” PMID 17198210 ↗ Dec 2006 “The combination of dexamethasone (DEX), ondansetron (OND) and droperidol (DRO) is efficacious in preventing postoperative nausea and vomiting in adults, but has not been well...” PMID 28505233 ↗ Jun 2017 “Guidelines recommend the combination of a neurokinin-1 receptor antagonist (NK1RA), 5-hydroxytryptamine-3 RA (5-HT3RA), and dexamethasone (DEX) for CINV prophylaxis in...” PMID 28285236 ↗ Mar 2017 “We therefore conducted a phase I/II study to establish the safety and preliminary efficacy of IXA with pomalidomide (POM) and dexamethasone (DEX) in lenalidomide (LEN)/PI-refractory MM.” PMID 34559902 ↗ Oct 2021 “The study will test a new combination of 3 drugs: Isatuximab (Isa), Iberdomide (Iber) and Dexamethasone (Dex), in patients who have intermediate or high risk smouldering myeloma.” NCT06762769 ↗ “The patients were allocated equally into 2 groups by block randomization to receive either loteprednol etabonate (Lot) or dexamethasone (Dex) for 1 month after the surgery.” PMID 25555173 ↗ Jan 2015 “The marked activity of thalidomide (thal) and dexamethasone (dex) in relapsed and refractory multiple myeloma (MM) provided the basis for this phase 2 clinical study” NCT01341262 ↗ “This study is a phase 1/2 study to assess safety and hematologic response rate of Ixazomib (MLN) in combination with Cyclophosphamide (CTX) and Dexamethasone (DEX).” NCT03236792 ↗ “Intrathyroid injection of dexamethasone (DEX) has been used to treat Graves' disease (GD); however, the mechanism of this treatment remains poorly understood.” PMID 22219499 ↗ Jan 2012 “The synthetic glucocorticoid dexamethasone (Dex) is a potent cortisol surrogate and glucocorticoid receptor (GR) agonist that resists 11βHSD2 inactivation.” NCT01769820 ↗ “received either four weekly glucocorticoid (dexamethasone [DEX]) or placebo administrations paired with a 45-second trauma memory reactivation task.” PMID 29466111 ↗ 2017 “perineural dexamethasone (DEX) versus dexmedetomidine (DEM) when used as adjuvants to ropivacaine in pediatric popliteal sciatic nerve blocks” PMID 41043950 ↗ Oct 2025 “preemptive single-dose etoricoxib, preemptive single-dose dexamethasone, and no premedication in impacted mandibular third molar surgery” NCT05791721 ↗ “To evaluate the ability to induce serum folate receptor (FR) with dexamethasone (Dex) and valproic acid (VPA) treatment” NCT02520115 ↗ “high-dose systemic methotrexate (MTX) and dexamethasone (DEX) combined with zidovudine (AZT) and brain irradiation” NCT00000723 ↗ “Dexamethasone (Dex): 20mg tablets taken during both treatment phase 1 (21 days \& treatment phase 2 (42 days)” NCT02290431 ↗ “Lenalidomide (Len) and Dexamethasone (Dex) for 6 months followed by three donor lymphocyte infusions (DLIs)” NCT03413800 ↗ “adjuvant dexamethasone (dex) and thalidomide (thal) in an attempt to reduce TRM and improve response rates.” NCT01527032 ↗ “Dex was presented as dexamethasone sulphate ampoules 8mg in 2ml. (Medical Union Pharmaceutical, Egypt MUP)” NCT03250494 ↗ “extended dexamethasone (Dex) treatment induces irreversible cell cycle blockade and a senescence phenotype” NCT04037462 ↗ “Daratumumab (DARA) in combination with pomalidomide (POM) and low-dose dexamethasone (dex) (DPd)” NCT03651128 ↗ “a dexamethasone intracanalicular insert (DEX) for treatment of allergic conjunctivitis (AC).” PMID 39328900 ↗ Sep 2024 “hepatic arterial floxuridine (FUDR) and dexamethasone (Dex) given via an implanted pump” NCT00059930 ↗ “Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate (B-DEX-MPA)” NCT05279092 ↗ “with hepatic arterial infusion (HAI) of floxuridine (FUDR) and dexamethasone (Dex)” PMID 19233901 ↗ Feb 2009 “Treatments including physical activity (PA) or dexamethasone (Dex) improve CRF;” PMID 34965510 ↗ Dec 2021 “Dexamethasone (DEX): 10 mg/m2 EV, IM or PO days 1-2, 8-9 days 15-16, 22-23. .” NCT01376427 ↗ “* Dexamethasone (DEX): 10 mg/m2 EV, IM or PO days 1-2, 8-9 days 15-16, 22-23.” NCT01358201 ↗ “HR20013 plus dexamethasone (DEX) versus fosaprepitant (FAPR) plus PALO + DEX” PMID 39621965 ↗ Dec 2024 “All subjects will receive TJ202 and dexamethasone (DEX) in the study.” NCT03860038 ↗ “preservative-free dexamethasone (DEX), diclofenac (DICLO) eye drops” PMID 36602718 ↗ Jan 2023 “The most striking results were seen with dexamethasone (Dex).” PMID 26707935 ↗ Dec 2015 “the use of 3-day dexamethasone (DEX) is often recommended” PMID 32735029 ↗ Aug 2020 “Dexamethasone (DEX) is the most frequently used steroid.” NCT04266977 ↗ “DEX (dexamethasone) 8 mg/m2 PO daily (tid) x 7 days” NCT00187005 ↗ “Dex 6 mg/m2 PO; in 3 divided doses daily x 7” NCT00187057 ↗ “floxuridine (FUDR)/dexamethasone (Dex)” PMID 21677464 ↗ Jun 2011 “dexamethasone sodium phosphate (DEX)” NCT03977454 ↗ “dexamethasone (Dex) orally” NCT03234972 ↗ “dexamethasone (Dex)” NCT00030069 ↗ “Dexamethasone (DEX)” NCT01862315 ↗ |
| Known as | Dex 21-P | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01171807 ↗ |
| Known as | DEX implant | “Dexamethasone intravitreal implant (DEX implant; OZURDEX, Allergan, Inc., Irvine, CA)” NCT01581151 ↗ |
| Known as | DEX, dexamethasone | “DEX, dexamethasone” NCT03629210 ↗ |
| Known as | DEX-I | “Dexamethasone Intravitreal Implant (DEX-I, 0.7 mg)” NCT07438119 ↗ |
| Known as | DEXA | “This paper describes the rationale and detailed protocol for a randomised controlled trial evaluating the efficacy of dexamethasone (DEXA) in reducing PES after PAE.” PMID 34725072 ↗ Nov 20212“Patients receive dexamethasone (DEXA) on days 8-28.” NCT00613457 ↗ “Patients receive dexamethasone (DEXA) on days 8-28” NCT00430118 ↗ |
| Known as | DexaEDO | “DexaEDO (dexamethasone) eyedrops without preservatives are applied additionally.” NCT01228149 ↗ |
| Known as | Dexametasone | “Drug: Dexametasone” NCT07068048 ↗ |
| Known as | Dexamethason | “dexamethason (d 1, 2, 8, 9, 15, 16, 22, 23, 20mg, oral/intravenous injection)” NCT04612582 ↗ |
| Known as | Dexamethasone (0.4mg) Insert | “Dexamethasone (0.4mg) Insert” NCT05116345 ↗ |
| Known as | Dexamethasone (Caspian Tamin Pharmaceutical Co, Rasht, Iran) | “Dexamethasone (Caspian Tamin Pharmaceutical Co, Rasht, Iran)” NCT03531970 ↗ |
| Known as | Dexamethasone (D) | “Dexamethasone (D)” NCT01858922 ↗ |
| Known as | Dexamethasone (Decadron) | “Dexamethasone (Decadron®)” NCT02128230 ↗ |
| Known as | Dexamethasone (Decadron, Baycadron) | “Dexamethasone (Decadron, Baycadron)” NCT01297764 ↗ |
| Known as | Dexamethasone (perineural) | “Dexamethasone (perineural)” NCT07584200 ↗ |
| Known as | Dexamethasone - MUP | “Packages and ampoules of dexamethasone and placebo will be identical and contain an equal volume of either a dexamethasone (Dexamethasone - MUP 8 MG / 2 ML (Dexamethasone...” NCT06783634 ↗ |
| Known as | Dexamethasone 21-Phosphate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04200885 ↗ |
| Known as | dexamethasone acetate | “Baycuten N® is a cream composed by clotrimazole 10mg and dexamethasone acetate 0.443 mg/g that will be dispensed to 80 participants of this group in the first stage.” NCT02582177 ↗16“Dexamethasone acetate: Take 12mg orally on the first day of each chemotherapy cycle before chemotherapy, and 3.75mg orally on the second to fourth days twice a day.” NCT07617246 ↗ “Dexamethasone acetate microspheres for extended-release injectable micro-suspension, SX600 at 12.5 mg or 25.0 mg” NCT03952377 ↗ “Dexamethasone/Dexamethasone acetate” NCT06979596 ↗ |
| Known as | Dexamethasone Disodium Phosphate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02955641 ↗ |
| Known as | Dexamethasone implant | “Patients will receive a Dexamethasone implant and ranibizumab, as needed.” NCT01581151 ↗ |
| Known as | Dexamethasone implants (Ozurdex, Allergan Inc., Irvine, CA, USA) | “Dexamethasone implants (Ozurdex®, Allergan Inc., Irvine, CA, USA)” NCT04089605 ↗ |
| Known as | Dexamethasone Inj (Dexamethasone disodium phosphate 5㎎) [Daewon Pharm] | “Dexamethasone Inj (Dexamethasone disodium phosphate 5㎎) [Daewon Pharm]” NCT06437054 ↗ |
| Known as | dexamethasone intravitreal implant | “Dexamethasone intravitreal implant (DEX implant; OZURDEX, Allergan, Inc., Irvine, CA)” NCT01581151 ↗ |
| Known as | Dexamethasone IV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05704049 ↗ |
| Known as | DEXAMETHASONE MYLAN code UCD 9223084 3400892230849 | “DEXAMETHASONE MYLAN code UCD 9223084 3400892230849” NCT02862327 ↗ |
| Known as | Dexamethasone Ophthalmic | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05387941 ↗ |
| Known as | Dexamethasone Oral | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06126354 ↗ |
| Known as | Dexamethasone Oral Tablet | “Drug: Dexamethasone Oral Tablet” NCT03199482 ↗ |
| Known as | Dexamethasone Sodium phosphate | “Oncocort Dexamethasone sodium phosphate encapsulated in so-called 'long-circulating' PEGylated liposomes is in development with the prospect of providing enhanced and prolonged...” NCT03033316 ↗41“Patients were treated with a combination of punctal dilation and topical medication in the form of preservative-free steroid eye drops based on dexamethasone sodium phosphate...” NCT06798025 ↗ “Packages and ampoules of dexamethasone and placebo will be identical and contain an equal volume of either a dexamethasone (Dexamethasone - MUP 8 MG / 2 ML (Dexamethasone...” NCT06783634 ↗ “Dexamethasone sodium phosphate (DSP) encapsulated in autologous erythrocytes (EryDex) was developed as an alternative to standard glucocorticoids in an effort to eliminate...” PMID 39917433 ↗ Jan 2025 “Two different commercially available eye drops will be compared: dexamethasone sodium phosphate (Maxidex®, Alcon) in one eye of the patient and artificial tears (Lacrystat®,...” NCT00266838 ↗ “This will be a randomized, double-blind, placebo-controlled clinical research trial testing the efficacy of intravenous dexamethasone sodium phosphate as adjuvant therapy for...” NCT00122278 ↗ “after which 1.4 mL of a mixture of 2 mg of dexamethasone sodium phosphate and 1 mL of 1% plain lidocaine will be slowly injected through the radiofrequency treatment cannula needle.” NCT03131466 ↗ “EryDex System (EDS) is a combination product used to administer dexamethasone sodium phosphate (DSP) by ex vivo encapsulation in autologous erythrocytes which are re-infused.” NCT02380924 ↗ “Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.” NCT04123561 ↗ “Once the microcatheter is in a good position, 15 mg Dexamethasone Sodium Phosphate and 15 mg of Ketorolac Tromethamine will be infused over 30 minutes.” NCT04353505 ↗ “The pulp chamber was irrigated with 2 mL of a dexamethasone sodium phosphate solution at a concentration of 4 mg/mL (Decort®, DEVA Holding, Türkiye).” NCT07233577 ↗ “20 mg of Prednisone or 1 mL of 4 mg/mL Dexamethasone Sodium Phosphate will be administered each day for participants in the intervention group” NCT04568837 ↗ “Drug Name: Dexamethasone Sodium phosphate Dose: 8mg of IV formula of dexamethasone is mixed with normal saline to make a total volume of 8ml.” NCT04027322 ↗ “TN-001, the study drug, is a topical eyedrop containing Transforming Growth Factor Beta 3 (TGFB3) and Dexamethasone Sodium Phosphate (DexSP).” NCT07388069 ↗ “Dexamethasone sodium phosphate 0.1% eye drops (Spersadex OmniVision, Novartis Pharma), one drop six times daily for three days in one eye.” NCT00476593 ↗ “0.4 mg in 0.1 ml dexamethasone (Dexamethasone sodium phosphate, Amriya Pharmaceuticals, Cairo, Egypt)” NCT05271539 ↗ “dexamethasone sodium phosphate (DSP) into autologous erythrocytes (EDS) creating the EDS-end product” NCT03563053 ↗ “one dose of IM dexamethasone sodium phosphate 8 mg (2 mL) given at the start of labour induction” NCT07109258 ↗ “Dexamethasone sodium phosphate (Epidron®, EIPICO, Cairo, Egypt) is supplied in 4 mg/ml ampule.” NCT03064633 ↗ “0,1mg/kg dexamethasone sodium phosphate - before the popliteal nerve block” NCT05887778 ↗ “Dexamethasone Sodium Phosphate Injection 20 mg” NCT06930690 ↗ “dexamethasone sodium phosphate 1mL (10mg/mL)” NCT04544683 ↗ “Dexamethasone Sodium Phosphate 10 MG/ML” NCT03382821 ↗ “dexamethasone sodium phosphate (DEX)” NCT03977454 ↗ “Drug: Dexamethasone sodium phosphate” NCT06951087 ↗ “Drug: Dexamethasone sodium phosphate” NCT03745105 ↗ |
| Known as | Dexamethasone Sodium Phosphate Injection | “This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available...” NCT04858776 ↗2“This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available...” NCT04862468 ↗ “0.6 mg/kg of Dexamethasone Sodium Phosphate Injection 10mg/1ml given with equivalent volume of cherry syrup given orally once” NCT02192827 ↗ |
| Known as | Dexamethasone sodium phosphate injection, 5 mg/1 mL | “Dexamethasone sodium phosphate injection, 5 mg/1 mL” NCT07576660 ↗ |
| Known as | Dexamethasone Sodium Sulfate | “Drug: Dexamethasone Sodium Sulfate” NCT00995501 ↗ |
| Known as | Dexamethasone tablets | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00923273 ↗ |
| Known as | Dexamethasone-21-Sulfobenzoate, Sodium Salt | “Drug: Dexamethasone-21-Sulfobenzoate, Sodium Salt” NCT02953210 ↗ |
| Known as | dexamethasonephosphate | “Patients received standard dexamethasone (dexamethasone-phosphate 6 mg/d for 10 days [or placebo prior to RECOVERY trial results communication]) or high-dose dexamethasone...” PMID 35788622 ↗ Sep 202220“Transscleral iontophoretic delivery of EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) delivered via EyeGate® II Drug Delivery System” NCT00765804 ↗ “20 mg of dexamethasonephosphate (Dexavit, Vital Pharma Nordic ApS, Denmark) or placebo” NCT05895838 ↗ “Is usually commercialized as dexamethasone phosphate as solution for injection” NCT04188431 ↗ “Moxifloxacin 0.5% and Dexamethasone Phosphate 0.1%” NCT06352541 ↗ “Drug: Dexamethasone phosphate” NCT04816097 ↗ “Drug: Dexamethasone phosphate” NCT05635227 ↗ “Dexamethasone phosphate” NCT04762381 ↗ |
| Known as | dexamethasonphosfat | “The dexamethasone kit will contain 20 mg of dexamethasonphosfat (Dexavit®,Vital Pharma Nordic), 4mg/mL, i.e. 5 mL, which corresponds to 16.67 mg of dexamethasone.” NCT05635227 ↗ |
| Known as | Dexamethesone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00431197 ↗ |
| Known as | Dexaven | “steroid therapy with Dexaven 4 mg / 1 ml - 2 injections at weekly intervals containing single doses of dexamethasone (total dose of 8 mg)” NCT04492774 ↗1“dexamethasone ((Dexaven 4mg/ml, Jelfa, Poland) in a dose of 4 mg will be administered intravenously” NCT06609993 ↗ |
| Known as | Dexavit | “The dexamethasone kit will contain 20 mg of dexamethasonphosfat (Dexavit®,Vital Pharma Nordic), 4mg/mL, i.e. 5 mL, which corresponds to 16.67 mg of dexamethasone.” NCT05635227 ↗ |
| Known as | DexSP | “TN-001, the study drug, is a topical eyedrop containing Transforming Growth Factor Beta 3 (TGFB3) and Dexamethasone Sodium Phosphate (DexSP).” NCT07388069 ↗ |
| Known as | Dextenza | “DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone...” NCT04521140 ↗19“Assessing the efficacy and safety of DEXTENZA, sustained release dexamethasone 0.4 mg inserts, when placed within the lower eye lid canaliculus or both the upper and lower canaliculi” NCT04501367 ↗ “Patient's first eye scheduled for surgery will receive an intracanalicular insertion of DEXTENZA (dexamethasone release profile of QID, TID, BID, QD, over 30 days; study eye).” NCT04479748 ↗ “Dextenza is a sustained-release dexamethasone intracanalicular insert recently approved by the FDA for pain and inflammation post ophthalmic surgery.” NCT04530864 ↗ “Dextenza is a sustained-release dexamethasone intracanalicular insert recently approved by the FDA for pain and inflammation post ophthalmic surgery.” NCT04426734 ↗ “Dextenza is a 0.4mg dexamethasone ophthalmic insert manufactured by Ocular Therapeutix.” NCT05587231 ↗ “Dextenza (dexamethasone ophthalmic insert 0.4mg) 1-3 days prior to cataract surgery” NCT04667507 ↗ “DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use” NCT05620901 ↗ “DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use” NCT04728646 ↗ “Dextenza (dexamethasone) 0.4mg intracanalicular insert delivery system” NCT04687800 ↗ “Ocular Therapeutix Dextenza (Dexamethasone Ophthalmic Insert) 0.4 mg” NCT04549935 ↗ “Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg)” NCT04527887 ↗ “Dextenza (Dexamethasone Ophthalmic Insert 0.4 mg)” NCT04563299 ↗ “Dextenza (dexamethasone ophthalmic insert) 0.4mg” NCT04316936 ↗ “Dexamethasone 0.4 MG [Dextenza]” NCT05100186 ↗ “Dexamethasone 0.4 MG [Dextenza]” NCT05143281 ↗ “DEXTENZA®” NCT04371445 ↗ |
| Known as | Dextenza Ophthalmic Insert | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04539548 ↗ |
| Known as | Dexycu | “A single 0.005-mL anterior chamber injection of DEXYCU (dexamethasoneintraocular suspension) 9%, equivalent to 517mcg dexamethasone.” NCT05191706 ↗2“Intracameral Dexamethasone (Dexycu™)” NCT04781335 ↗ “Dexycu intracameral dexamethasone” NCT04273282 ↗ |
| Known as | disaimisong | “doxorubicin hydrochloride iposome (duomeisu) plus bortizomib (velcade) and dexamethasone (disaimisong)” NCT02577783 ↗ |
| Known as | DSP | “Dexamethasone sodium phosphate (DSP) encapsulated in autologous erythrocytes (EryDex) was developed as an alternative to standard glucocorticoids in an effort to eliminate...” PMID 39917433 ↗ Jan 20255“dexamethasone sodium phosphate (DSP) encapsulated in autologous erythrocytes” NCT06664853 ↗ “dexamethasone sodium phosphate \[DSP\] in autologous erythrocytes” NCT06193200 ↗ “dexamethasone sodium phosphate (DSP) ophthalmic solution” NCT07395232 ↗ |
| Known as | DSP-Visulex | “dexamethasone sodium phosphate Visulex (DSP-Visulex)” NCT02309385 ↗ |
| Known as | DxaM | “The addition of dexamethasone (DxaM) to local anesthetic may significantly prolong the duration of a block.” NCT02190760 ↗ |
| Known as | DXM | “This study compared the efficacy and safety of high-dose dexamethasone (HD-DXM) and conventional prednisone (PDN) on the largest cohort to date as first-line strategies for...” PMID 26480931 ↗ Oct 201517“AIM: To investigate the beneficial and harmful effects of one or two doses of 24 mg intravenous dexamethasone (DXM) as part of a multimodal analgesic regimen (paracetamol,...” PMID 31544230 ↗ Oct 2019 “In this study we want to investigate if combination therapy with rituximab (R) + dexamethasone (DXM) is superior to monotherapy with DXM in patients with newly diagnosed...” NCT00909077 ↗ “Patients in this group will receive a standard root canal treatment but with the extra step of extruding a Dexamethasone (DXM) solution through the root canals to the...” NCT06894069 ↗ “The participants in DXM group will receive a single infusion of a paravertebral space first dose of 21 ml of analgesic containing 0.5 percentage ropivacaine 20 ml and...” NCT05920967 ↗ “The respective benefits of high and low doses of dexamethasone (DXM) in patients with severe acute respiratory syndrome coronavirus 2 (SARS-Cov2) and acute respiratory failure...” PMID 37634234 ↗ Aug 2023 “Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)” NCT02529774 ↗ “Male and female volunteers received one dose of DXM. Drugs formulations employed were DXM phosphate injectable solution 8 mg/2 mL (Alin, Productos Farmaceuticos, Mexico).” NCT05647408 ↗ “Intravenous (IV) or oral dexamethasone (DXM) reduced 28 d mortality in patients who required supplemental oxygen compared to those who received conventional care alone.” PMID 38290199 ↗ Jan 2024 “Dexamethasone (DXM) instead of PDN is given to all patients with T-ALL without any high-risk criteria as identified by day 8.” NCT01117441 ↗ “The induction therapy is a combination of Blinatumomab(Blina), Vindesine(VDS), Cyclophosphamide(CTX) and Dexamethasone(DXM).” NCT06742515 ↗ “Dexamethasone (DXM): week1-2: 10 mg/m2.d, week 3-4: 5 mg/m2.d, week5-6: 2.5 mg/m2.d, week7: 1.25 mg/m2.d, week8: tapering.” NCT05491304 ↗ “Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution)” NCT02400047 ↗ “Cyclophosphamide + Doxorubicin + Vincristine + Dexamethasone (DXM)] ± Rituximab” NCT06520163 ↗ “Dexamethasone and Hydroxychloroquine (HCQ/DXM)” NCT04347980 ↗ “DXM(dexamethasone),40mg/d,p.o,d1-4” NCT02520219 ↗ “Dexamethasone (DXM ) :” NCT02036489 ↗ “Dexamethasone (DXM):” NCT00526305 ↗ |
| Known as | EGP-437 | “Transscleral iontophoretic delivery of EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) delivered via EyeGate® II Drug Delivery System” NCT00765804 ↗6“ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS)” NCT01602068 ↗ “Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)” NCT01129856 ↗ “Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)” NCT02485249 ↗ “Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)” NCT01505088 ↗ “Iontophoresis Delivery of Dexamethasone Phosphate (EGP-437) at one of three different iontophoretic doses.” NCT01059955 ↗ |
| Known as | Epidron | “Dexamethasone sodium phosphate (Epidron®, EIPICO, Cairo, Egypt) is supplied in 4 mg/ml ampule.” NCT03064633 ↗ |
| Known as | epidrone | “the product dexamethasone sodium phosphate intramuscular one hour before the initiation of labor induction in the form of epidrone ampoules which is a dexamethasone product...” NCT03603418 ↗ |
| Known as | Episcleral Dexamethasone | “This phase I trial will assess primarily the safety and secondarily anti-inflammatory effect of Episcleral Dexamethasone in patients suffering from refractory diabetic macular edema.” NCT04005430 ↗ |
| Known as | EryDex | “Dexamethasone sodium phosphate (DSP) encapsulated in autologous erythrocytes (EryDex) was developed as an alternative to standard glucocorticoids in an effort to eliminate...” PMID 39917433 ↗ Jan 20251“EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)” NCT01925859 ↗ |
| Known as | EryDex System (dexamethasone sodium phosphate encapsulated erythrocytes) | “EryDex System (dexamethasone sodium phosphate encapsulated erythrocytes)” NCT01925859 ↗ |
| Known as | Fortecortin | “The patients in the dexamethasone group will receive 12mg dexamethasone (Fortecortin ®) intravenously 15-60 minutes prior to surgery while in general anasthesia as well as 12mg...” NCT05120076 ↗2“Dexamethasone (Fortecortin®) will be acquired from ERN, SA. Laboratories (Barcelona, Spain).” NCT04303065 ↗ “Fortecortin/Dexamethasone 8 mg/2 ml inj. subacromial 3 times at days 1, 8 and 15” NCT01702233 ↗ |
| Known as | FST-201 | “FST-201 (dexamethasone 0.1%) Otic Suspension” NCT00945646 ↗1“FST-201 (dexamethasone 0.1%) Otic Suspension” NCT00945802 ↗ |
| Known as | Glucocorticoid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05916781 ↗ |
| Known as | HD-DXM | “Therapy of Adults affected by idiopathic thrombocytopenic purpura with 3 cycles pulses of high-dose dexamethasone (HD-DXM): a prospective randomized clinical trial” NCT02914054 ↗5“High-dose dexamethasone (HD-DXM) will be administered orally (40 mg) from day 1-4, followed by Arm 1 or 2 (1:1 randomization).” NCT04812483 ↗ “Dexamethasone (HD-DXM) at a dose of 40mg/d for 4 days constitutes one cycle.” NCT06992128 ↗ “Dexamethasone (HD-DXM) 40mg/d × 4 days, one cycle.” NCT06658834 ↗ “Adjunction of dexamethasone (HD DXM)” NCT00777738 ↗ “high-dose dexamethasone [HD-DXM]” NCT00657410 ↗ |
| Known as | hexadecadrol | “methimazole,tapazole;dexamethasone,hexadecadrol” NCT00917241 ↗ |
| Known as | i.v dexmethasone | “Drug: i.v dexmethasone” NCT04778189 ↗ |
| Known as | IDI | “Dextenza (IDI) (Sustained Release Dexamethasone), (0.4 mg)” NCT04527887 ↗ |
| Known as | Inj Dexona | “2 ml in dexamethasone ( 4mg/ml Inj Dexona, Zydus Aliadac, India)” NCT04850885 ↗ |
| Known as | ISV-305 | “The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy of ISV-305 (Dexamethasone in DuraSite® 2) compared to Vehicle” NCT03192150 ↗1“ISV-305 (0.1% Dexamethasone in DuraSite® 2)” NCT03192137 ↗ |
| Known as | liposome adriamycin | “Bendamustine 70-90mg/m2, d1, d2 Liposome Adriamycin 15-20mg/m2, d1 or Adriamycin 10mg d1-d4 Dexamethasone 40mg qw po.” NCT05006469 ↗1“Epirubicin 75 mg/m2 i.v d1 or liposome adriamycin 35mg/m2 i.v d1(21-day cycles)” NCT05887726 ↗ |
| Known as | Maxidex | “Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane Ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon...” NCT05331859 ↗7“A Randomized, Double-Masked, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of Maxidex® (0.1% Dexamethasone) Ophthalmic Suspension and Patanol® (0.1%...” NCT01119287 ↗ “Two different commercially available eye drops will be compared: dexamethasone sodium phosphate (Maxidex®, Alcon) in one eye of the patient and artificial tears (Lacrystat®,...” NCT00266838 ↗ “Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye...” NCT04050644 ↗ “dexamethasone ophthalmic suspension (Maxidex®)” NCT03739528 ↗ |
| Known as | Mephamesone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01945554 ↗ |
| Known as | Methyprednisolone | “methyprednisolone” NCT02981212 ↗ |
| Known as | Monofree Dexamethason | “Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye...” NCT04050644 ↗ |
| Known as | Monopex | “Preservative free dexamethasone 0.1% (Monopex) drops for one week” NCT05433428 ↗ |
| Known as | Mylan Dexamethasone | “Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution)” NCT02400047 ↗ |
| Known as | Neofordex | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04968899 ↗ |
| Known as | NSC-34521 | “Intrathecal Dexamethasone, IT DM, NSC-34521” NCT00002499 ↗ |
| Known as | OCS-01 | “The goal of this study was to compare topical dexamethasone 1.5% in a novel formulation (OCS-01) once daily and BID versus vehicle for the treatment of inflammation and pain...” PMID 36503736 ↗ Dec 20222“Drug: Dexamethasone ophthalmic suspension (OCS-01)” NCT05066997 ↗ “Dexamethasone ophthalmic suspension (OCS-01)” NCT06172257 ↗ |
| Known as | Oncocort | “Oncocort Dexamethasone sodium phosphate encapsulated in so-called 'long-circulating' PEGylated liposomes is in development with the prospect of providing enhanced and prolonged...” NCT03033316 ↗ |
| Known as | Oradexon | “dexamethasone (Oradexon, Nederland)” NCT00548483 ↗ |
| Known as | Oral dexamethasone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02234466 ↗ |
| Known as | OTO-104 | “single intratympanic injection of either 12 mg OTO-104 (otic formulation of dexamethasone in thermosensitive poloxamer) or placebo (1:1) and were observed for 3 months.” PMID 37185596 ↗ Apr 2023 |
| Known as | OTX-DED | “OTX-DED (dexamethasone intracanalicular ophthalmic insert)” NCT04747977 ↗1“OTX-DED (dexamethasone intracanalicular ophthalmic insert)” NCT05814757 ↗ |
| Known as | OTX-DP | “To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of ocular...” NCT01666210 ↗5“The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid...” NCT02062905 ↗ “The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid...” NCT02445326 ↗ “OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and pain in subjects...” NCT02089113 ↗ “OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use” NCT02468700 ↗ “OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use” NCT02736175 ↗ |
| Known as | OZURDEX | “OZURDEX® (DEX implant, 0.7 mg) is a micro-ionized and non-preserved dexamethasone within a cylindrically-shaped 0.45 mm diameter x 6.5 mm length biodegradable Poly D,...” NCT03629210 ↗28“Ozurdex (Dexamethasone): intravitreal implant as per commercial label (700 µg Dexamethasone; Dexamethasone was formulated as a rod shaped implant to be inserted into the eye by...” NCT01580020 ↗ “The purpose of this study is to determine whether an intravitreal dexamethasone implant (Ozurdex, Allergan) is effective to manage macular edema secondary to non-infectious uveitis.” NCT01870440 ↗ “OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.” NCT01903720 ↗ “The main purpose of this study is to evaluate whether or not the dexamethasone pellet (Ozurdex®, Allergan, Irvine, CA) can replace oral corticosteroid” NCT02049476 ↗ “Comparator Ozurdex® (dexamethasone) was formulated as a rod shaped implant to be inserted into the eye by an applicator.” NCT01396057 ↗ “intravitreal sustained release dexamethasone implant (Ozurdex®) injected at the conclusion of surgery” NCT01701518 ↗ “Ozurdex® (dexamethasone intravitreal (IVT) implant, 0.7 mg)” NCT06536491 ↗ “intravitreal dexamethasone implant (Ozurdex®)” NCT02399657 ↗ “dexamethasone intravitreal implant (Ozurdex)” NCT01410201 ↗ “Ozurdex (dexamethasone) given intravitreally” NCT01787669 ↗ “OZURDEX® Implant 700 µg (Dexamethasone)” NCT03908307 ↗ “Drug: Dexamethasone implant OZURDEX” NCT02834260 ↗ |
| Known as | Ozurdex (dexamethasone intravitreal implant) | “Ozurdex® (dexamethasone intravitreal implant)” NCT01295112 ↗1“OZURDEX® (dexamethasone intravitreal implant)” NCT01478737 ↗ |
| Known as | Phapros | “Ibuprofen (Peinlos) 2x400 mg iv, Paracetamol (Bernofarm) 2x1 gr iv, dexamethasone (Phapros) 2x5 mg iv will be given with interval 8 hour, within the IBU-PCT-DEX intervention.” NCT06604598 ↗ |
| Known as | ProDex | “Phase I/II Trial of TLC399 (ProDex) in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)” NCT02006147 ↗1“TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)” NCT03093701 ↗ |
| Known as | Scorpion antivenom | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06333834 ↗ |
| Known as | SMO1 | “SMO1 (Dexamethasone 700μg intravitreal implant)” NCT07708142 ↗ |
| Known as | Soldesam 0.2% | “Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).” NCT00786851 ↗ |
| Known as | Spersadex | “Topical dexamethasone 1 mg/ml (Spersadex) started the day after surgery” NCT05331690 ↗3“Topical dexamethasone 1 mg/ml (Spersadex)” NCT05072262 ↗ “Spersadex 1 mg/ml 20 days after surgery” NCT05433428 ↗ “Spersadex” NCT01748942 ↗ |
| Known as | Spersadex (OmniVision, Novartis Pharma)eye drops. | “Spersadex (OmniVision, Novartis Pharma)eye drops.” NCT00476593 ↗ |
| Known as | Spersadex OmniVision, Novartis Pharma | “Dexamethasone sodium phosphate 0.1% eye drops (Spersadex OmniVision, Novartis Pharma), one drop six times daily for three days in one eye.” NCT00476593 ↗ |
| Known as | Sterodex | “Dexamethasone (Sterodex)” NCT02825186 ↗ |
| Known as | SX600 | “Dexamethasone acetate microspheres for extended-release injectable micro-suspension, SX600 at 12.5 mg or 25.0 mg” NCT03952377 ↗ |
| Known as | TLC399 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02006147 ↗ |
| Known as | TLC399 (BioSeizer) | “TLC399 (BioSeizer)” NCT02006147 ↗ |
| Known as | Visumetazone | “Visumetazone” NCT01748942 ↗ |
| Action | Activate | “Choline magnesium trisalicylate +/- dexamethasone decreased nuclear NF-kappaB, whereas dexamethasone alone was associated with an increase in nuclear NF-kappaB in AML cells.” PMID 19010875 ↗ Nov 2008 |
| Modality | Small molecule | “dexamethasone-a strong steroid medication” NCT00004990 ↗ |
| Route | Oral | “A fifth medicine (dexamethasone) is given by mouth (PO) on days 1 - 5 of each cycle” NCT00000689 ↗ |
| Target | HDAC2 | “The 3C-like proteinase on SARS-CoV-2 (nsp5) inhibits HDAC2 transport into the nucleus, and so impairs the way in which it mediates inflammation and cytokine responses, so...” NCT04530409 ↗ |